WO2014064277A1 - Vector for liver-directed gene therapy of hemophilia and methods and use thereof - Google Patents
Vector for liver-directed gene therapy of hemophilia and methods and use thereof Download PDFInfo
- Publication number
- WO2014064277A1 WO2014064277A1 PCT/EP2013/072450 EP2013072450W WO2014064277A1 WO 2014064277 A1 WO2014064277 A1 WO 2014064277A1 EP 2013072450 W EP2013072450 W EP 2013072450W WO 2014064277 A1 WO2014064277 A1 WO 2014064277A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- subject
- hemophilia
- plasma
- equal
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 284
- 238000000034 method Methods 0.000 title claims abstract description 58
- 208000009292 Hemophilia A Diseases 0.000 title claims abstract description 48
- 238000001415 gene therapy Methods 0.000 title abstract description 48
- 208000031220 Hemophilia Diseases 0.000 title description 23
- 102100022641 Coagulation factor IX Human genes 0.000 claims abstract description 223
- 108010076282 Factor IX Proteins 0.000 claims abstract description 174
- 229960004222 factor ix Drugs 0.000 claims abstract description 155
- 230000014509 gene expression Effects 0.000 claims abstract description 143
- 210000004185 liver Anatomy 0.000 claims abstract description 71
- 230000001105 regulatory effect Effects 0.000 claims abstract description 65
- 208000009429 hemophilia B Diseases 0.000 claims abstract description 54
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract description 38
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 28
- 102100026735 Coagulation factor VIII Human genes 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 201000003542 Factor VIII deficiency Diseases 0.000 claims abstract description 25
- 108700019146 Transgenes Proteins 0.000 claims description 85
- 150000007523 nucleic acids Chemical class 0.000 claims description 68
- 230000001225 therapeutic effect Effects 0.000 claims description 56
- 108050000761 Serpin Proteins 0.000 claims description 54
- 102000008847 Serpin Human genes 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 239000003001 serine protease inhibitor Substances 0.000 claims description 53
- 239000003623 enhancer Substances 0.000 claims description 52
- 241000282414 Homo sapiens Species 0.000 claims description 51
- 108010071690 Prealbumin Proteins 0.000 claims description 39
- 108010020764 Transposases Proteins 0.000 claims description 39
- 102000009190 Transthyretin Human genes 0.000 claims description 39
- 230000008488 polyadenylation Effects 0.000 claims description 39
- 102000008579 Transposases Human genes 0.000 claims description 38
- 238000010361 transduction Methods 0.000 claims description 38
- 230000026683 transduction Effects 0.000 claims description 38
- 239000013603 viral vector Substances 0.000 claims description 36
- 230000035772 mutation Effects 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 238000001890 transfection Methods 0.000 claims description 28
- 102000001690 Factor VIII Human genes 0.000 claims description 26
- 108010006025 bovine growth hormone Proteins 0.000 claims description 19
- 240000007019 Oxalis corniculata Species 0.000 claims description 16
- 241000702421 Dependoparvovirus Species 0.000 claims description 15
- 229960000301 factor viii Drugs 0.000 claims description 15
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229940105778 coagulation factor viii Drugs 0.000 claims description 10
- 229940105774 coagulation factor ix Drugs 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 229940065638 intron a Drugs 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 241000702623 Minute virus of mice Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 102000013831 Coagulation factor IX Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 111
- 241000699670 Mus sp. Species 0.000 description 92
- 108090000623 proteins and genes Proteins 0.000 description 78
- 241000699666 Mus <mouse, genus> Species 0.000 description 61
- 230000000694 effects Effects 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 42
- 239000002299 complementary DNA Substances 0.000 description 41
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 27
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 26
- 239000013607 AAV vector Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 24
- 241000700605 Viruses Species 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 210000003494 hepatocyte Anatomy 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 18
- 238000013518 transcription Methods 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 238000012546 transfer Methods 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000035602 clotting Effects 0.000 description 13
- 238000011144 upstream manufacturing Methods 0.000 description 13
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 12
- 208000034158 bleeding Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 238000001476 gene delivery Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 102000057593 human F8 Human genes 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002440 hepatic effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000006058 immune tolerance Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 6
- 241000649044 Adeno-associated virus 9 Species 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 230000017105 transposition Effects 0.000 description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003154 D dimer Substances 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012411 cloning technique Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 208000031169 hemorrhagic disease Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 108010089996 B-domain-deleted factor VIII Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020608 Hypercoagulation Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000026578 Severe hemophilia B Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010013935 factor IX-Padua Proteins 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002477 vacuolizing effect Effects 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000132028 Bellis Species 0.000 description 1
- 206010005176 Blindness congenital Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000823435 Homo sapiens Coagulation factor IX Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710084218 Master replication protein Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 101710112078 Para-Rep C2 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940031422 benefix Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940052349 human coagulation factor ix Drugs 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000018592 inherited blood coagulation disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102200147804 rs193929360 Human genes 0.000 description 1
- 102220215480 rs780747709 Human genes 0.000 description 1
- 102200067145 rs80356929 Human genes 0.000 description 1
- 239000013609 scAAV vector Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 241001147420 ssDNA viruses Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14341—Use of virus, viral particle or viral elements as a vector
- C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Definitions
- the invention relates to expression vectors for gene therapy with improved liver-specific expression capabilities, particularly for use as a gene therapy means for the treatment of hemophilia, more particularly for restoring coagulation factor IX (FIX) and/or coagulation factor VIII (FVIII) in liver-directed gene therapy of respectively, hemophilia B and hemophilia A.
- FIX coagulation factor IX
- FVIII coagulation factor VIII
- Hemophilia B is an X-linked, recessive bleeding disorder caused by deficiency of clotting factor IX (FIX).
- FIX clotting factor IX
- the clinical presentation for hemophilia B is characterized by episodes of spontaneous and prolonged bleeding. There are an estimated 1 in 20,000 individuals who suffer from hemophilia B.
- hemophilia B is treated with protein replacement therapy using either plasma-derived or recombinant FIX.
- FIX protein replacement markedly improved the life expectancy of patients suffering from hemophilia, they are still at risk for severe bleeding episodes and chronic joint damage, since prophylactic treatment is restricted by the short half-life, the limited availability and the high cost of purified FIX, which can approach 100.000$/patient/year.
- Hemophilia A is a serious bleeding disorder caused by a deficiency in, or complete absence of, the blood coagulation factor VIII (FVIII).
- the severity of hemophilia A and hemophilia B has been classified by the subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis into three forms, depending on respectively, the FVIII level and the FIX level: 1 ) severe form (FVIII or FIX level less than 0.01 international units (IU)/ml, i.e. less than lU/ml, i.e.
- IU international units
- Hemophilia A is the most common hereditary coagulation disorder with an incidence approaching approximately 1 in 5000 males.
- Protein substitution therapy with purified or recombinant FVIII has significantly improved the patients' quality of life.
- PST is not curative and patients are still at risk of developing potentially life-threatening hemorrhages and crippling joint inflammation.
- many patients suffering from hemophilia A develop neutralizing antibodies to FVIII (i.e. "inhibitors") following PST. These inhibitors complicate the management of bleeding episodes and can render further PST ineffective.
- Inhibitors neutralizing antibodies to FVIII
- These limitations of PST justify the development of gene therapy as a potential alternative for hemophilia treatment.
- only a modest increase in FVIII plasma concentration is needed for therapeutic benefit, with levels of more than 1 % of normal levels able to achieve markedly reduced rates of spontaneous bleeding and long-term arthropathy.
- the liver is the main physiological site of FIX and FVIII synthesis and hence, hepatocytes are well suited target cells for hemophilia gene therapy. From this location, FIX protein can easily enter into the circulation. Moreover, the hepatic niche may favor the induction of immune tolerance towards the transgene product (Annoni et al., 2007; Follenzi et al., 2004; Brown et al., 2007; Herzog et al., 1999; Matrai et al., 201 1 ; Matsui et al., 2009).
- Liver-directed gene therapy for hemophilia can be accomplished with different viral vectors including retroviral (Axelrod et al., 1990; Kay et al., 1992; VandenDriessche et al., 1999, Xu et al., 2003, 2005), lentiviral (Ward et al., 201 1 , Brown et al., 2007, Matrai et al., 201 1 ), adeno-associated viral (AAV) (Herzog et al., 1999) and adenoviral vectors (Brown et al., 2004)(Ehrhardt & Kay, 2002).
- retroviral Alrod et al., 1990; Kay et al., 1992; VandenDriessche et al., 1999, Xu et al., 2003, 2005
- lentiviral Ward et al., 201 1 , Brown et al., 2007, Matrai et al., 201 1
- AAV is a naturally occurring replication defective non-pathogenic virus with a single stranded DNA genome.
- AAV vectors have a favorable safety profile and are capable of achieving persistent transgene expression. Long-term expression is predominantly mediated by episomally retained AAV genomes. More than 90% of the stably transduced vector genomes are extra-chromosomal, mostly organized as high-molecular-weight concatamers. Therefore, the risk of insertional oncogenesis is minimal, especially in the context of hemophilia gene therapy where no selective expansion of transduced cells is expected to occur.
- AAV-mediated hepatic gene transfer is an attractive alternative for gene therapy of hemophilia for both liver and muscle-directed gene therapy (Herzog et al., 1997, 1999, 2002; Arruda et al., 2010; Fields et al., 2001 ; Buchlis et al., 2012; Jiang et al., 2006; Kay et al., 2000).
- AAV serotypes could be used (e.g. AAV8 or AAV5) that result in increased transduction into hepatocytes, improve intra-nuclear vector import and reduce the risk of T cell activation (Gao et al., 2002; Vandenberghe et al., 2006).
- Liver-directed gene therapy for hemophilia B with AAV8 or AAV9 is more efficient than when lentiviral vectors are used, at least in mice, and resulted in less inflammation (VandenDriessche et al., 2007, 2002).
- liver-directed preclinical studies paved the way toward the use of AAV vectors for clinical gene therapy in patients suffering from severe hemophilia B.
- Hepatic delivery of AAV-FIX vectors resulted in transient therapeutic FIX levels (maximum 12% of normal levels) in subjects receiving AAV-FIX by hepatic artery catheterization (Kay et al., 2000).
- the transduced hepatocytes were able to present AAV capsid-derived antigens in association with MHC class I to T cells (Manno et al., 2006, Mingozzi et al., 2007). Although antigen presentation was modest, it was sufficient to flag the transduced hepatocytes for T cell-mediated destruction.
- AAV8 allows for a substantial increase in hepatic transduction compared to AAV2, though this advantage may be lost in higher species, like dog, rhesus monkeys and man.
- Subjects received escalating doses of the scAAV8-FIX vector, with two participants per dose. All of the treated subjects expressed FIX above the therapeutic 1 % threshold for several months after vector administration, yielding sustained variable expression levels (i.e. 2 to 1 1 % of normal levels).
- sustained variable expression levels i.e. 2 to 1 1 % of normal levels.
- the main difference with the previous liver-directed AAV trial is that for the first time sustained therapeutic FIX levels could be achieved after gene therapy.
- T-cell mediated clearance of AAV-transduced hepatocytes remains a concern consistent with elevated liver enzyme levels in some of the patients. Transient immune suppression using a short course of glucocorticoids was used in an attempt to limit this vector-specific immune response.
- FVIII constructs in which the B domain is deleted are used for gene transfer purposes since their smaller size is more easily incorporated into vectors. Furthermore, it has been shown that deletion of the B domain leads to a 17-fold increase in mRNA and primary translation product.
- FVIII wherein the B domain is deleted and replaced by a short 14-amino acid linker is currently produced as a recombinant product and marketed as Refacto® for clinical use (Wyeth Pharma) (Sandberg et al., 2001 ).
- Miao et al. added back a short B domain sequence to a B domain deleted FVIII, optimally 226 amino acids and retaining 6 sites for N-linked glycosylation, to improve secretion.
- Mcintosh et al. (2013) replaced the 226 amino-acid spacer of Miao et al. with a 17 amino-acid peptide in which six glycosylation triplets from the B-domain were juxtaposed. Yet, production was still not sufficient for therapeutic purposes.
- Non-viral vectors typically rely on a plasmid-based gene delivery system, where only the naked DNA is delivered, potentially in conjunction with physicochemical methods that facilitate transfection. Consequently, the non-viral approach maybe less immunogenic and potentially safer than viral vectors, though innate immune response may still occur.
- the non-viral gene transfer method is simple, but the efficiency is generally low compared to most viral vector-mediated gene transfer approaches. Efficient in vivo gene delivery of non-viral vectors remains a bottleneck. Typically, for hepatic gene delivery, plasmids are administered by hydrodynamic injection.
- a hydrodynamic pressure is generated by rapid injection of a large volume of DNA solution into the circulation, in order to deliver the gene of interest in the liver (Miao et al., 2000).
- Efforts are being made to adapt hydrodynamic injection towards a clinically relevant modality by reducing the volume of injection along with maintaining localized hydrodynamic pressure for gene transfer.
- Alternative approaches based on targetable nanoparticles are being explored to achieve target specific delivery of FIX into hepatocytes. Expression could be prolonged by removing bacterial backbone sequences which interfere with long term expression (i.e. mini-circle DNA)
- transposons could be used that result in stable genomic transgene integration.
- transposons could be used to obtain stable clotting factor expression following in vivo gene therapy (Yant et al., 2000; Mates, Chuah et al., 2009, VandenDriessche et al., 2009; Kren et al.,2009; Ohlfest et al., 2004 ).
- FIX liver-specific expression of FIX
- WO2009/130208 An exemplary state of the art vector for liver-specific expression of FIX is described in WO2009/130208 and is composed of a single-stranded AAV vector that contains the TTR/Serp regulatory sequences driving a factor cDNA.
- a FIX first intron was included in the vector, together with a poly-adenylation signal.
- Using said improved vector yielded about 25-30% stable circulating factor IX.
- FIX transgenes optimized for codon usage and carrying an R338L amino acid substitution associated with clotting hyperactivity and thrombophilia increase the efficacy of gene therapy using lentiviral vector up to 15-fold in hemophilia B mice, without detectable adverse effects, substantially reducing the dose requirement for reaching therapeutic efficacy and thus facilitating future scale up and its clinical translation (Cantore et al., 2012).
- the above objective is accomplished by providing a vector, either a viral vector, in particular an AAV-based vector, or a non-viral vector, in particular a transposon-based vector, comprising a nucleic acid expression cassette with specific regulatory elements that enhance liver-directed gene expression, while retaining tissue specificity, in conjunction with the use of a human FIX gene containing a hyper- activating mutation and/or a codon-optimized transgene.
- the resulting vector and nucleic acid expression cassette results in unexpectedly high expression levels of FIX in the liver, due to its unique combination of regulatory elements and the choice of vector type and transgene. The combined effect of these elements could not have been predicted.
- the given AAV-based vector yielded about 25-30% stable circulating factor IX.
- the new vector obtained 500-600% of stable circulating factor IX levels. This represents a more than 20- fold increase in FIX levels due to the unique combination of elements of the nucleic acid expression cassette and vector of the present invention.
- Example 7 the inventors demonstrated in Example 7 that specific combinations of the Serpin enhancer (called “Serp” or “SerpEnh” herein) with codon-optimized hFIX transgene or the Serpin enhancer with transgene encoding hFIX containing the Padua mutation provide for synergistic effects on FIX activity.
- Serpin Serpin enhancer
- SerpinEnh codon-optimized hFIX transgene
- the highest hFIX activity was measured in mice hydrodynamically injected with a plasmid comprising the unique combination of the Serpin enhancer with a codon-optimized transgene encoding hFIX containing the Padua mutation.
- hFIX activity in these mice was up to 265-fold higher as compared to hFIX acitivity in mice injected with a corresponding hFIX plasmid without the Serpin enhancer, the codon-optimization and the Padua mutation. This increase in hFIX activity was shown to be synergistic.
- this objective is accomplished by providing a vector either a viral vector, in particular an AAV- based vector, or a non-viral vector, in particular a transposon-based vector, comprising a nucleic acid expression cassette with specific regulatory elements that enhance liver- directed gene expression, while retaining tissue specificity, in particular the Serpin enhancer, in conjunction with the use of a codon-optimized human FVIII construct, in particular a codon-optimized B domain deleted FVIII construct.
- the resulting AAV-based vector and nucleic acid expression cassette resulted in unprecedented, supra-physiologic FVIII expression levels (i.e. more than 200% of normal level) using relatively low vector doses (5x10 9 vg/mouse).
- Example 6 The inventors demonstrated in Example 6 that the specific combination of the Serpin enhancer with the codon-optimized B domain deleted FVIII transgene provides for a synergistic effect on FVIII expression levels compared to expression cassettes containing either the Serpin enhancer or the codon-optimized B domain deleted FVIII transgene.
- a vector comprising a nucleic acid expression cassette comprising a liver- specific regulatory element, a promoter, optionally a minute virus of mouse (MVM) intron, a transgene, preferably a codon-optimized transgene, and a transcriptional termination signal.
- MVM minute virus of mouse
- Aspect 2 The vector according to aspect 1 , wherein said transgene encodes for factor VIII or factor IX.
- Aspect 3 The vector according to aspect 2, wherein said coagulation factor VIII has a deletion of the B domain.
- Aspect 4 The vector according to aspect 3, wherein said B domain of said FVIII is replaced by a linker having SEQ ID NO:16.
- Aspect 5 The vector according to aspect 2, wherein said coagulation factor IX contains a hyper-activating mutation.
- Aspect 6 The vector according to aspect 5, wherein said hyper-activating mutation in coagulation factor IX corresponds to an R338L amino acid substitution.
- Aspect 7 The vector according to any one of aspects 2 to 6, wherein said transgene encoding for coagulation factor VIII or IX is codon-optimized.
- Aspect 8 The vector according to any one of aspects 1 to 4, or 7, wherein said transgene encoding for coagulation factor VIII has SEQ ID NO:7.
- Aspect 9 The vector according to any one of aspects 1 to 8, wherein said liver-specific regulatory element contains sequences from the serpin promoter.
- liver-specific regulatory element comprises or consists of SEQ ID NO:8, or a sequence having 95% identity to said sequence, preferably wherein said liver-specific regulatory element is the Serpin enhancer.
- Aspect 1 The vector according to any one of aspects 1 to 10, wherein said promoter is derived from the transthyretin (TTR) promoter, preferably the minimal TTR promotor.
- TTR transthyretin
- Aspect 12 The vector according to any one of aspects 1 to 1 1 , wherein said transcriptional termination signal is derived from the bovine growth hormone polyadenylation signal or from the Simian virus 40 polyadenylation signal.
- Aspect 13 The vector according to any one of aspects 1 to 12, wherein said vector is a viral vector.
- Aspect 14 The vector according to aspect 13, wherein said vector is derived from an adeno-associated virus (AAV), preferably AAV serotype 9.
- AAV adeno-associated virus
- Aspect 15 The vector according to aspect 14, wherein said vector is a single-stranded AAV, preferably single-stranded AAV serotype 9.
- Aspect 16 The vector according to any one of aspects 1 to 4, 7 to 15, having SEQ ID NO: 6, or the vector according to any one of aspects 1 , 2, 5 to 7, 9 to 15, or 17, having SEQ ID NO: 1 or 2.
- Aspect 17 The vector according to aspect 14, wherein said vector is a self- complementary AAV, preferably self-complementary AAV serotype 9.
- Aspect 18 The vector according to any one of claims 1 to 12, wherein said vector is a non-viral vector.
- Aspect 19 The vector according to aspect 18, wherein said vector is a transposon-based vector.
- Aspect 20 The vector according to aspect 19, wherein said vector is a PiggyBac(PB)- based vector, such as the PB-based vector having SEQ ID NO:13, preferably a PiggyBac- based vector comprising micro inverted repeats, more preferably the PB-based vector having SEQ ID NO: 14 or 15, or a Sleeping Beauty(SB)-based vector, preferably the SB- based vector having SEQ ID NO:16.
- PB PiggyBac(PB)- based vector
- PB-based vector having SEQ ID NO:13 preferably a PiggyBac- based vector comprising micro inverted repeats, more preferably the PB-based vector having SEQ ID NO: 14 or 15, or a Sleeping Beauty(SB)-based vector, preferably the SB- based vector having SEQ ID NO:16.
- Aspect 22 The method according to aspect 21 , wherein the transduction of the vector according to any one of claims 1 to 4, 7 to 17 into the subject is done at a dose lower than 2.5x10 11 vg/kg.
- a method to obtain levels of factor IX in plasma equal to or higher than the therapeutic threshold concentration of 10mU/ml plasma in a subject comprising the transduction or transfection of the vector according to any one of aspects 1 , 2, 5 to 15, 17 to 20 into a subject.
- Aspect 24 The method according to aspect 23, wherein the transduction of the vector according to any one of aspects 1 , 2, 5 to 15, 17 into the subject is done at a dose lower than 2x10 11 vg/kg.
- Aspect 24 The method according to aspect 23, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 100 mU/ml in a subject, wherein the transduction of the vector according to any one of aspects 1 , 2, 5 to 15, 17 into the subject is done at a dose lower than or equal than 6x10 11 vg/kg.
- Aspect 25 The method according to aspect 23, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 50 mU/ml in a subject, wherein the transduction of the vector according to any one of aspects 1 , 2, 5 to 15, 17 into the subject is done at a dose lower than or equal than 6x10 11 vg/kg.
- Aspect 26 The method according to aspect 23, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 200 mU/ml in a subject, wherein the transduction of the vector according to any one of aspects 1 , 2, 5 to 15, 17 into the subject is done at a dose lower than or equal than 2x10 12 vg/kg.
- Aspect 27 The method according to aspect 23, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 150 mU/ml in a subject, wherein the transduction of the vector according to any one of claims 1 , 2, 5 to 15, 17 into the subject is done at a dose lower than or equal than 2x10 12 vg/kg.
- Aspect 28 The method according to any one of aspects 21 to 27, wherein said transduction or transfection is by intravenous administration.
- Aspect 29 The method according to any one of aspects 21 or 23, wherein said transfection is by hydrodynamic transfection.
- Aspect 30 The method according to any one of aspects 21 , 23, 28 or 29, wherein a vector according to any one of aspects 19 or 20 is administered in combination with a vector encoding a transposase, preferably a hyperactive transposase.
- Aspect 31 The method according to any one of aspects 21 to 30, wherein said subject is a mammalian subject, preferably a human subject.
- Aspect 32 A method for treating hemophilia A in a mammalian subject, comprising performing the method according to any one of aspects 21 , 22, 28 to 31.
- Aspect 33 The use of the vector according to any one of aspects 1 to 4, 7 to 20 for the manufacture of a medicament to treat hemophilia A.
- Aspect 34 The vector according to any one of aspects 1 to 4, 7 to 20 for use in the treatment of hemophilia A.
- Aspect 35. A method for treating hemophilia B in a mammalian subject, comprising performing the method according to any one of aspects 23 to 31 .
- Aspect 36 The use of the vector according to any one of aspects 1 , 2, 5 to 15, 17 to 20 for the manufacture of a medicament to treat hemophilia B.
- Aspect 37 The vector according to any one of aspects 1 , 2, 5 to 15, 17 to 20 for use in the treatment of hemophilia B.
- a pharmaceutical composition comprising a vector according to any one of aspects 1 to 4, 7 to 20 and a pharmaceutically acceptable carrier, optionally further comprising an active ingredient for treating hemophilia A.
- Aspect 39 The pharmaceutical composition according to aspect 38 for use in treating hemophilia A.
- Aspect 40 The pharmaceutical composition for use according to aspect 39, or the vector for use according to aspect 34, wherein said treatment results in levels of factor VIII in plasma of the treated subject that are equal to or higher than the therapeutic threshold concentration of 10 mU/ml plasma in a subject.
- Aspect 41 The pharmaceutical composition for use according to any one of aspects 39 or 40, or the vector for use according to any one of aspects 34 or 40, wherein said treatment comprises the transduction of the vector according to any one of claims 1 to 4, 7 to 17 into the subject at a dose lower than or equal than 2.5x10 11 vg/kg.
- a pharmaceutical composition comprising a vector according to any one of aspects 1 , 2, 5 to 15, 17 to 20 and a pharmaceutically acceptable carrier, optionally further comprising an active ingredient for treating hemophilia B.
- Aspect 43 The pharmaceutical composition according to aspect 42, for use in treating hemophilia B.
- Aspect 44 The pharmaceutical composition for use according to aspect 43, or the vector for use according to aspect 37, wherein said treatment results in levels of factor IX in plasma of the treated subject that are equal to or higher than the therapeutic threshold concentration of 10 mU/ml plasma in a subject, preferably equal to or higher than the therapeutic concentration of 50 mU/ml plasma in a subject, more preferably equal to or higher than the therapeutic concentration of 100 mU/ml plasma in a subject, even more preferably equal to or higher than the therapeutic concentration of 150 mU/ml plasma in a subject and even more preferably equal to or higher than the therapeutic concentration of 200 mU/ml plasma in a subject.
- Aspect 45 The pharmaceutical composition for use according to aspect 43, or the vector for use according to aspect 37, wherein said treatment results in levels of factor IX in plasma of the treated subject that are equal to or higher than the therapeutic threshold concentration of 10 mU/ml plasma in a subject, preferably equal to or higher than the therapeutic concentration of 50 mU/ml plasma in
- composition for use according to aspect 43 or 44, or the vector for use according to aspect 37 or 44, wherein said treatment comprises the transduction of the vector according to any one of aspects 1 , 2, 5 to 15, 17 to 20 into the subject at a dose lower than or equal than 2x10 12 vg/kg, preferably at a dose lower than or equal than 6x10 11 vg/kg, more preferably at a dose lower than or equal than 2x10 11 vg/kg.
- Figure 1 A shows a schematic diagram of the AAV9-SerpEnh-TTRm-MVM-co-hFIX construct (pdsAAVsc SerpTTRmMVMF9coptpA) with indication where the liver-specific Serpin regulatory element (“Serp” or "SerpEnh”) is inserted upstream of the transthyretin minimal promoter (TTRm).
- ITR viral inverted terminal repeat
- mTTR minimal transthyretin promoter
- MVM minute virus mouse
- huFIXcoptMT codon- optimized FIX
- bGHpA polyadenylation signal of bovine growth hormone
- B) shows the sequence of the AAV9-SerpEnh-TTRm-MVM-co-hFIX construct (SEQ ID No. 1 )
- C) shows the sequence of the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L construct (SEQ ID No. 2).
- FIG. 2 shows FIX activity after intravenous injection of AAV9-SerpEnh-TTRm-MVM-co- hFIX construct (pdsAAVsc SerpTTRmMVMF9coptpA) or AAV9-SerpEnh-TTRm-MVM-co- hFIX-R338L construct in FIX-deficient hemophilia B mice.
- AAV vectors expressing either the human codon-optimized FIX cDNA were designated as AAV-co-hFIX or the human codon-optimized FIX-R338L cDNA as AAV-co-padua-hFIX.
- hFIX activity levels were determined using a chromogenic activity assay on citrated plasma. Mice were injected with different vectors dose of the cognate self-complementary AAV9 vectors (10 9 vg, 5x10 9 vg, 2x10 10 vg).
- FIG. 3 A shows a schematic representation of the AAV9sc-SerpEnh-TTRm-MVM-co- hFIX-R338L vector.
- the expression cassette was packaged in a self-complimentary (sc) adeno-associated virus serotype 9 (AAV9), flanked by the 5' and 3' AAV inverted terminal repeats (ITR).
- the liver-specific minimal transthyretin (TTRm) promoter drives the codon- optimized human FIX with R338L mutation (co-hFIX-R338L) transgene.
- the hepatocyte- specific regulatory elements (“Serp” or "SerpEnh”) are located upstream of the TTRm promoter.
- VMM mouse mini-intron
- pA bovine growth hormone polyadenylation site
- B) shows a schematic representation of a control vector AAV9-SerpEnh-TTRm-MVM-co-hFIX, which is identical to the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector, but the transgene, codon- optimized hFIX, does not contain the R338L mutation.
- C) compares the R338L or Padua mutation in human FIX fragment (SEQ ID NO:23), making hFIX hyper-functional, with human FIX fragment (SEQ ID NO:24).
- mice were intravenously administered 1x10 9 vg/mouse (A,B), 5x10 9 vg/mouse (C,D) or 2x10 10 vg/mouse (E,F) of AAV9sc-SerpEnh-TTRm-MVM-co- hFIX-R338L (indicated as cohFIX-R338L) or AAV9sc-SerpEnh-TTRm-MVM-co-hFIX- (indicated as cohFIX) vector.
- hFIX activity A, C, E
- hFIX protein B, D, F
- hFIX expression (hFIX protein) was compared to the corresponding FIX clotting activity.
- J D-dimer levels and hFIX activity were determined in mice injected with AAV9sc-SerpEnh-TTRm-MVM-co-hFIX-R338L (indicated as AAV cohFIX R338L) or AAV9sc-SerpEnh-TTRm-MVM-co-hFIX (indicated as AAV cohFIX) vector at the indicated doses and compared to non-injected control mice. D-dimer levels were determined by ELISA and hFIX activity was analyzed by chromogenic assay. The D-dimer positive control is shown.
- A, B AAV copy number relative to 100 ng of genomic DNA was determined for both constructs at a dose of 1x10 9 vg/mouse (A) and 5x10 9 vg/mouse (B).
- C Quantitative reverse transcriptase (qRT)-PCR analysis of hFIX mRNA levels in the different organs expressed relative to hFIX mRNA levels in the liver for both constructs at a dose of 1x10 9 vg/mouse (C) and 5x10 9 vg/mouse (D). GAPDH was used for normalization. Results are presented as meaniSEM. * : p ⁇ 0.05, ** : p ⁇ 0.01 , *** : p ⁇ 0.001 (t- test).
- FIG. 6 A shows a schematic representation of AAVss-SerpEnh-TTRm-MVM- hFVIIIcopt-sv40pA vector.
- the expression cassette was packaged in a single-stranded (ss) adeno-associated virus, flanked by the 5' and 3' AAV inverted terminal repeats (ITR).
- the liver-specific minimal transthyretin (TTRm) promoter regulates transcription of the human codon-optimized B-domain deleted FVIII cDNA (hFVIIIcopt).
- the Serpin enhancer ("Serp" or "SerpEnh)is cloned upstream of the TTRm promoter.
- AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt-sv40pA construct shows a schematic of the AAVss- SerpTTRm-MVM-FVIIIcopt-sv40pA construct with indication where the liver-specific Serpin enhancer ("Serp" or "SerpEnh") is inserted upstream of the transthyretin minimal promoter (TTRm).
- ITR viral inverted terminal repeat
- MVM intron minute virus mouse intron
- FVIIIcopt codon-optimized B domain deleted human FIX
- SvpolyA polyadenylation signal of SV40.
- C) shows the sequence of the AAVss-SerpEnh-TTRm- MVM-hFVIIIcopt -sv40pA construct (SEQ ID NO. 6).
- flanking inverted terminal repeat sequences are indicated in italics, the Serpin enhancer ("Serp” or “SerpEnh”) in bold (72 bp), the minimal transthyretin promoter (TTRm) is underlined (202 bp), the mTTR/5' untranslated region is boxed (21 bp), the MVM intron is in italics and underlined (92bp), the codon-optimized B domain deleted hFVIII (hFVIIIcopt) underlined and in bold (4377 bp), and the SV40 polyadenylation sequence is in italics and bold and underlined (134 bp).
- E Nucleotide sequence of the Serpin enhancer ("Serp” or “SerpEnh”) (SEQ ID NO: 8).
- F Nucleotide sequence of the minimal transthyretin promoter (TTRm) (SEQ ID NO: 9).
- G Nucleotide sequence of the minute virus mouse (MVM) intron (SEQ ID NO: 10).
- FIG. 7 shows FVIII expression levels in CB17.SCID mice in function of time (days) following intravenous injection with AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt-sv40pA (5x10 9 vg/mouse).
- FVIII levels were determined using a hFVIII-specific ELISA and are expressed as a percentage of normal levels (i.e. physiological level of human FVIII of 200 ng/ml or 1 lU/ml of FVIII in a normal individual) and in ng/ml plasma.
- Figure 8 A shows a schematic of the plasmid pcDNA3_mouseCO_hyPiggyBac_Transposase_MT encoding codon-optimized hyperactive PiggyBac (PB) transposase.
- C) shows a schematic of the PB_Minimal_T_(T53C-
- TTRm liver-specific minimal transthyretin
- Serpin enhancer Serp
- SerpinEnh Serpin enhancer
- D) Nucleotide sequence of the PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA_D4Z4 transposon (SEQ ID NO: 13).
- E) schematically shows the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_bghpA transposon. Codon-optimized human FIX expression is driven from the liver-specific minimal transthyretin (TTRm) promoter operably linked to the Serpin enhancer ("Serp" or "SerpEnh”). The minute virus of mouse mini-intron (MVM) and bovine growth hormone polyadenylation signal (bghpA) are indicated.
- TTRm liver-specific minimal transthyretin
- Serp Serpin enhancer
- bghpA bovine growth hormone polyadenylation signal
- PB_micro_T_No_ins_TTRminSerpMVM_FIXco_bghpA transposon (SEQ ID NO:14).
- G) schematically shows the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_Padua_bghpA transposon. Codon-optimized human Padua FIX expression is driven from the liver-specific minimal transthyretin (TTRm) promoter operably linked to the Serpin enhancer ("Serp" or "SerpEnh”). The minute virus of mouse mini-intron (MVM) and bovine growth hormone polyadenylation signal (bghpA) are indicated.
- H Nucleotide sequence of the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_Padua_bghpA transposon (SEQ ID NO: 15).
- SB Sleeping Beauty
- pT2BH_TTRminSerpMVM_hFIXco_bghpA transposon Codon-optimized human FIX expression is driven from the liver-specific minimal transthyretin (TTRm) promoter operably linked to the Serpin enhancer ("Serp" or "SerpEnh”).
- TTRm minimal transthyretin
- Serpin enhancer Serpin enhancer
- the minute virus of mouse mini-intron (MVM) and bovine growth hormone polyadenylation signal (bghpA) are indicated.
- J) shows a schematic of the plasmid pCDNA3 _CMVBGI _SBMAX_bghpA encoding the hyperactive SBmax transposase.
- K) Nucleotide sequence of the pCDNA3 _CMVBGI _SBMAX_bghpA plasmid (SEQ ID NO:17).
- Figure 9. FIX expression levels in hemophilia B mice treated by liver-directed gene therapy using hyperactive PB transposon expressing either codon-optimized FIX or the hyperactive codon-optimized FIX-R338L mutant. The amount of transposon (IRpBAc miC ro) and transposase plasmid (hypBase) is indicated.
- FIG. 11 Comparison of Sleeping Beauty transposon and PiggyBac transposon for codon-optimized hFIX hepatic gene delivery. Sleeping Beauty transposon (pT2BH_TTRminSerpMVM_hFIXco_bghpA) and PiggyBac transposon
- PB_micro_T_NoJns_SerpTTrminMVM_hFIXco_BGHpA were injected in immunodeficient (NOD SCID) mice along with plasmid encoding codon-optimized hyperactive PB transposase (pcDNA3_mouseCO_hyPiggyBac_Transposase_MT) or hyperactive SBmax transposase (pCDNA3 _CMVBGI _SBMAX_bghpA), respectively using the doses as indicated.
- pcDNA3_mouseCO_hyPiggyBac_Transposase_MT hyperactive SBmax transposase
- pCDNA3 _CMVBGI _SBMAX_bghpA hyperactive SBmax transposase
- FIG. 12 Evaluation of effect of cloning MVM intron into nucleic acid constructs on in vivo expression of transgenes.
- A Schematic representation of the piggyBac transposon encoding for a wild-type hFIX (denoted as pB_hFIXIA) The expression cassette is flanked by the wild-type piggyBac transposon invert repeat (IRpBac).
- the liver-specific minimal transthyretin (TTRm) promoter drives the human FIX transgene comprising a truncated 1 ;4 kb hFIX intron A between exon 1 and the following exons 2-8.
- the hepatocyte-specific regulatory element (“Serp” or “SerpEnh”) is located upstream of the TTRm promoter. Bovine growth hormone polyadenylation site (pA) is also indicated.
- the hFIX transgene is codon-optimized (hFIXco) and contains no intron A. MVM intron is cloned upstream of the FIXco transgene.
- C Schematic representation of the mouse piggyBac transposase plasmid (denoted as mpBase).
- the mouse codon- optimized native piggyBac transposase (mpB) driven by the cytomegalovirus (CMV) promoter is cloned upstream of a ⁇ -globin intron ( ⁇ ).
- Bovine growth hormone polyadenylation site (bghpA) is also indicated.
- D Schematic representation of the empty control plasmid (denoted as empty) without a transposase gene.
- the plasmid contains a multiple cloning site (MCS) between the CMV promoter and the bghpa polyadenylation signal.
- MCS multiple cloning site
- mice Hemophilia B mice were hydrodynamically injected with 10 ⁇ g of transposon plasmids comprising wild-type hFIX transgene and truncated intron A (pB_hFIXIA, E) or codon-optimized hFIX transgene and MVM intron (pB_MVM-FIXco, F) in conjunction with 2 ⁇ g of plasmids encoding mouse piggyBac transposase (+ mpBase, full lines) or an empty control plasmid (+ empty, dashed lines) hFIX antigen expression (black squares) and hFIX clotting activity (grey squares) were measured on plasma samples collected at the indicated times by ELISA and a chromogenic hFIX activity assay, respectively.
- transposon plasmids comprising wild-type hFIX transgene and truncated intron A (pB_hFIXIA, E) or codon-optimized
- Transposon copies per diploid genome (G) and hFIX mRNA levels (H) were measured by a quantitative RT-PCR method (qRT-PCR) at the end of the experiments from total RNA extracted from liver biopsies.
- hFIX mRNA levels relative to FIXIA mRNA levels are shown in H.
- FIG. 13 Comparison of nucleic acid expression cassettes comprising hFVIII transgene.
- A,B Predicted (a,b) and measured (c,d) hFVIII levels in mice hydrodynamically injected with, from left to right, (a) AAV9ss-TTRm-MVM-hFVIII-SV40pA plasmid, (b) AAV9ss- SerpEnh-TTRm-MVM-hFVIII-SV40pA plasmid, (c) AAV9ss-TTRm-MVM-hFVIIIcopt- SV40pA plasmid, or (d) AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid, at 2 ⁇ g DNA (A) or 5 ⁇ g DNA (B).
- FIG. 14 shows the data for mice that were injected with 2 ⁇ g DNA
- FIG. 14 shows the data for mice that were injected with 5 ⁇ g DNA.
- Figure 14 Comparison of nucleic acid expression cassettes comprising hFIX transgene.
- A,B Bars showing from left to right, hFIX activity in mice hydrodynamically injected with (a) AAVsc-TTRm-MVM-hFIX-SV40pA plasmid; (b) AAVsc-SerpEnh-TTRm-MVM-hFIX- SV40pA plasmid; (c) AAVsc-TTRm-MVM-hFIXco-SV40pA plasmid; (b) and (c) calculated as the sum of hFIX activity measured in mice injected with (b) and (c); and (d) AAVsc- SerpEnh-TTRm-MVM-hFIXco-SV40pA plasmid at day 2 (A) and day 6 (
- FIG. 15 Schematic representation of the piggyBac transposon pB_hFIXco/IR mu ti6- wherein the expression cassette is flanked by a wild-type piggyBac transposon inverted repeat (IRwt) and a piggybac transposon inverted repeat containing the indicated point mutations (IRmut16).
- the liver-specific minimal transthyretin (TTRmin) promoter drives a codon-optimized hFIX (hFIXco). Minute virus of mouse (MVM) intron is cloned upstream of the FIXco transgene.
- the Serpin enhancer (denoted as HSH8) is located upstream of the TTRmin promoter.
- Bovine growth hormone polyadenylation site (pA) is also indicated.
- B Schematic representation of the piggybac transposon pB_hFIXco/IR miC ro- The transposon is the same as pB_hFIXco/IR mu ti6, except for the inverted repeats, which are micro inverted repeats (IRmicro).
- C Schematic representation of the piggybac transposon pB_hFIXco-R338L. The transposon is the same as pB_hFIXco/IR miC ro, except for the transgene which is codon-optimized human FIX containing the Padua mutation (hFIXco-R338L).
- FIG. D Schematic representation of the hyperactive piggyBac transposase (hyPBase) plasmid.
- the hyperactive piggyBac transposase (hyPBase) driven by the cytomegalovirus (CMV) promoter is cloned upstream of a ⁇ -globin intron ( ⁇ ).
- CMV cytomegalovirus
- bghpA Bovine growth hormone polyadenylation site
- mice Three months after transfection with pB transposons pB_hFIXIA, pB_hFIXco, or pB_hFIXco-R338L, mice were subjected to immunization with recombinant hFIX antigen and adjuvant. Anti-hFIX specific antibodies were measured by ELISA at week 2 (black) and week 4 (grey) post-immunization (p.i). PBS-injected hemophilia B mice that were immunized with recombinant hFIX and adjuvant were used as positive control. Results are presented as mean ⁇ standard error of the mean. n.s.
- coagulation factor IX has the meaning as known in the art. Synonyms of coagulation factor IX are “FIX” or “Christmas factor” or “F9” and can be used interchangeably. In particular, the term “coagulation factor IX” encompasses the human protein encoded by the mRNA sequence as defined in Genbank accession number NM_000133.
- said FIX is a mutated FIX, which is hyperactive or hyper-functional as compared to the wild type FIX.
- Modifying functional activity of human coagulation factor can be done by bioengineering e.g. by introduction of point mutations.
- a hyperactive R338A variant was reported, which showed a 3 fold increased clotting activity compared to the wild type human FIX in an in vitro activated partial thromboplastin time assay (APPT) (Chang et al., 1998) and a 2 to 6-fold higher specific activity in hemophilia B mice transduced with the mutant FIX gene (Schuettrumpf et al., 2005).
- APPT in vitro activated partial thromboplastin time assay
- FIX FIX
- EGF-1 domain replaced with the EGF-1 domain from FVII, alone or in combination with a R338A point mutation
- V86A/E277A/R338A triple mutant Li et al., 2010
- Y259F, K265T, and/or Y345T single, double or triple mutants Milanov, et al., 2012
- G190V point mutant Kao et al., 2010
- the FIX mutant is the one described by Simioni et al., in 2009 and denominated as the "factor IX Padua" mutant, causing X-linked thrombophilia. Said mutant factor IX is hyperactive and carries an R338L amino acid substitution.
- the FIX transgene used in expression vector encodes the human FIX protein, most preferably the FIX transgene encodes for the Padua mutant of the human FIX protein.
- coagulation factor VIII has the meaning as known in the art. Synonyms of coagulation factor VIII are “FVIN” or “anti-hemophilic factor” or “AHF” and can be used interchangeably herein.
- the term “coagulation factor VIII” encompasses, for example, the human protein having the amino acid sequence as defined in Uniprot accession number P00451 .
- said FVIII is a FVIII wherein the B domain is deleted (i.e. B domain deleted FVIII, also referred to as BDD FVIII or FVIIIAB herein).
- B domain deleted FVIII encompasses for example, but without limitation, FVIII mutants wherein whole or a part of the B domain is deleted and FVIII mutants wherein the B domain is replaced by a linker.
- Non-limiting examples of B domain deleted FVIII are described in Ward et al. (201 1 ) and WO 201 1/005968, which are specifically incorporated by reference herein.
- said FVIII is B domain deleted FVIII wherein the B domain is replaced by a linker having the following sequence: SFSQNPPVLTRHQR (SEQ ID NO: 16) (i.e. SQ FVIII as defined in Ward et al. (201 1 )).
- said FVIII has SEQ ID NO:7 (i.e. codon-optimized B domain deleted human FVIII or hFVIIIcopt), as disclosed also in WO 201 1/0059.
- a “regulatory element” as used herein refers to transcriptional control elements, in particular non-coding cis-acting transcriptional control elements, capable of regulating and/or controlling transcription of a gene, in particular tissue-specific transcription of a gene.
- Regulatory elements comprise at least one transcription factor binding site (TFBS), more in particular at least one binding site for a tissue-specific transcription factor, most particularly at least one binding site for a liver-specific transcription factor.
- TFBS transcription factor binding site
- regulatory elements as used herein increase or enhance promoter-driven gene expression when compared to the transcription of the gene from the promoter alone, without the regulatory elements.
- regulatory elements particularly comprise enhancer sequences, although it is to be understood that the regulatory elements enhancing transcription are not limited to typical far upstream enhancer sequences, but may occur at any distance of the gene they regulate. Indeed, it is known in the art that sequences regulating transcription may be situated either upstream (e.g. in the promoter region) or downstream (e.g. in the 3'UTR) of the gene they regulate in vivo, and may be located in the immediate vicinity of the gene or further away.
- regulatory elements as disclosed herein typically are naturally occurring sequences, combinations of (parts of) such regulatory elements or several copies of a regulatory element, i.e. non-naturally occurring sequences, are themselves also envisaged as regulatory element. Regulatory elements as used herein may be part of a larger sequence involved in transcriptional control, e.g. part of a promoter sequence. However, regulatory elements alone are typically not sufficient to initiate transcription, but require a promoter to this end.
- the regulatory elements contained in the nucleic acid expression cassettes and vectors disclosed herein are preferably liver-specific.
- Non-limiting examples of liver-specific regulatory elements are disclosed in WO 2009/130208, which is specifically incorporated by reference herein.
- the regulatory element in the nucleic acid expression cassettes and vectors disclosed herein is a liver-specific regulatory element derived from the serpin gene promotor.
- Siad regulatory element comprises the sequence as defined in SEQ ID NO:8, a sequence having at least 85%, preferably at least 90%, more preferably at least 95%, such as 96%, 97%, 98% or 99%, identity to said sequence, or a functional fragment thereof.
- Said regulatory element is herein referred to as "the Serpin enhancer", "SerpEnh”, or "Serp".
- the regulatory element in the nucleic acid expression cassettes and vectors disclosed herein consists of the sequence defined by SEQ ID NO:8 (i.e. the Serpin enhancer, also called “SerpEnh”, or “Serp” herein).
- liver-specific expression' refers to the preferential or predominant expression of a (trans)gene (as RNA and/or polypeptide) in the liver as compared to other tissues. According to particular embodiments, at least 50% of the (trans)gene expression occurs within the liver. According to more particular embodiments, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% of the (trans)gene expression occurs within the liver. According to a particular embodiment, liver-specific expression entails that there is no 'leakage' of expressed gene product to other organs, such as spleen, muscle, heart and/or lung.
- hepatocyte-specific expression which may be considered as a particular form of liver-specific expression.
- liver-specific is mentioned in the context of expression
- hepatocyte-specific expression is also explicitly envisaged.
- tissue-specific expression is used in the application, cell-type specific expression of the cell type(s) predominantly making up the tissue is also envisaged.
- fragments refers to fragments of the sequences disclosed herein that retain the capability of regulating liver-specific expression, i.e. they still confer tissue specificity and they are capable of regulating expression of a (trans)gene in the same way (although possibly not to the same extent) as the sequence from which they are derived.
- Fragments comprise at least 10 contiguous nucleotides from the sequence from which they are derived. In further particular embodiments, fragments comprise at least 15, at least 20, at least 25, at least 30, at least 35 or at least 40 contiguous nucleotides from the sequence from which they are derived.
- nucleic acid expression cassette refers to nucleic acid molecules that include one or more transcriptional control elements (such as, but not limited to promoters, enhancers and/or regulatory elements, polyadenylation sequences, and introns) that direct (trans)gene expression in one or more desired cell types, tissues or organs. Typically, they will also contain the FIX transgene or the FVIII transgene as defined herein.
- transcriptional control elements such as, but not limited to promoters, enhancers and/or regulatory elements, polyadenylation sequences, and introns
- operably linked refers to the arrangement of various nucleic acid molecule elements relative to each such that the elements are functionally connected and are able to interact with each other.
- Such elements may include, without limitation, a promoter, an enhancer and/or a regulatory element, a polyadenylation sequence, one or more introns and/or exons, and a coding sequence of a gene of interest to be expressed (i.e., the transgene).
- the nucleic acid sequence elements when properly oriented or operably linked, act together to modulate the activity of one another, and ultimately may affect the level of expression of the transgene. By modulate is meant increasing, decreasing, or maintaining the level of activity of a particular element.
- the position of each element relative to other elements may be expressed in terms of the 5' terminus and the 3' terminus of each element, and the distance between any particular elements may be referenced by the number of intervening nucleotides, or base pairs, between the elements.
- promoter refers to nucleic acid sequences that regulate, either directly or indirectly, the transcription of corresponding nucleic acid coding sequences to which they are operably linked (e.g. a transgene or endogenous gene).
- a promoter may function alone to regulate transcription or may act in concert with one or more other regulatory sequences (e.g. enhancers or silencers).
- a promoter is typically operably linked to regulatory elements to regulate transcription of a transgene.
- the regulatory element when operably linked to both a promoter and a transgene, the regulatory element can (1 ) confer a significant degree of liver specific expression in vivo (and/or in hepatocytes/ hepatic cell lines in vitro) of the transgene, and/or (2) can increase the level of expression of the transgene in the liver (and/or in hepatocytes/hepatocyte cell lines in vitro).
- the promoter contained in the nucleic acid expression cassettes and vectors disclosed herein is a liver-specific promoter.
- the liver-specific promoter is from the transthyretin (TTR) gene.
- the TTR promoter is a minimal promoter (also referred to as TTRm, mTTR or TRRmin herein), most particularly the minimal TTR promoter as defined in SEQ ID NO: 9.
- the promoter in the nucleic acid expression cassettes and vectors disclosed herein is a minimal promoter.
- a 'minimal promoter' as used herein is part of a full-size promoter still capable of driving expression, but lacking at least part of the sequence that contributes to regulating (e.g. tissue-specific) expression.
- This definition covers both promoters from which (tissue- specific) regulatory elements have been deleted- that are capable of driving expression of a gene but have lost their ability to express that gene in a tissue-specific fashion and promoters from which (tissue-specific) regulatory elements have been deleted that are capable of driving (possibly decreased) expression of a gene but have not necessarily lost their ability to express that gene in a tissue-specific fashion.
- Minimal promoters have been extensively documented in the art, a non-limiting list of minimal promoters is provided in the specification.
- the nucleic acid expression cassette in the expression vector according to the invention comprises a plasmid origin, a promotor and/or enhancer, a (trans)gene, a transcription terminator, and a selection gene.
- nucleic acid expression cassette in the expression vector according to the invention comprises the following elements:
- ITR Inverted Terminal Repeat sequence
- an enhancer preferably the Serpin enhancer ("Serp” or “SerpEnh”),
- TTRm minimal TTR promoter
- a transcription terminator preferably a polyadenylation signal such as the bGHpA,
- a selection gene e.g. an antibiotic resistance gene such as an ampicilin resistance gene
- plasmid origin such as the pBR322 origin.
- the cloning of the MVM intron into a nucleic acid expression cassette described herein was shown to unexpectedly high expression levels of the transgene operably linked thereto.
- said nucleic acid expression cassette in the expression vector comprises the following elements (cf. Figure 1 ):
- ITR Inverted Terminal Repeat sequence
- an enhancer preferably the Serpin enhancer ("Serp” or “SerpEnh”),
- TTRm minimal TTR promoter
- an intron sequence preferably the MVM intron
- a transcription terminator preferably a polyadenylation signal such as the bGHpA,
- a selection gene e.g. an antibiotic resistance gene such as an ampicilin resistance gene
- plasmid origin such as the pBR322 origin.
- the vector is an adeno-associated virus-derived vector, in combination with the Padua-mutant FIX gene.
- said nucleic acid expression cassette in the vector comprises the following elements:
- a plasmid origin such as the f1 Origin
- ITR Inverted Terminal Repeat sequence
- liver-specific regulatory element preferably the Serpin enhancer
- a promoter preferably the minimal TTR promoter
- an intron sequence preferably the MVM intron
- a (trans)gene preferably codon-optimized factor VIII cDNA, even more preferably codon- optimized B domain deleted factor VIII cDNA, - a transcription terminator, preferably a polyadenylation signal such as the Simian vacuolating virus 40 or Simian virus 40 (SV40) polyadenylation signal,
- a polyadenylation signal such as the Simian vacuolating virus 40 or Simian virus 40 (SV40) polyadenylation signal
- a selection gene e.g. an antibiotic resistance gene such as an ampicilin resistance gene
- plasmid origin such as the pBR322 origin.
- the vector is an adeno-associated virus(AAV)-derived vector in combination with codon-optimized B domain deleted FVIII cDNA.
- said nucleic acid expression cassette in the vectors disclosed herein comprises:
- liver-specific regulatory element preferably the Serpin enhancer
- a promoter preferably the minimal TTR promoter
- a transcription terminator preferably a polyadenylation signal such as the bovine growth hormone polyadenylation signal.
- said nucleic acid expression cassette in the vectors disclosed herein comprises:
- liver-specific regulatory element preferably the Serpin enhancer
- a promoter preferably the minimal TTR promoter
- an intron sequence preferably the MVM intron
- a transcription terminator preferably a polyadenylation signal such as the bovine growth hormone polyadenylation signal
- said nucleic acid expression cassette in the vectors disclosed herein comprises:
- liver-specific regulatory element preferably the Serpin enhancer, - a promoter, preferably the minimal TTR promoter
- an intron sequence preferably the MVM intron
- a transcription terminator preferably a polyadenylation signal such as the Simian vacuolating virus 40 or Simian virus 40 (SV40) polyadenylation signal,
- transgene refers to particular nucleic acid sequences encoding a polypeptide or a portion of a polypeptide to be expressed in a cell into which the nucleic acid sequence is inserted. However, it is also possible that transgenes are expressed as RNA, typically to lower the amount of a particular polypeptide in a cell into which the nucleic acid sequence is inserted.
- RNA molecules include but are not limited to molecules that exert their function through RNA interference (shRNA, RNAi), micro-RNA regulation (miR), catalytic RNA, antisense RNA, RNA aptamers, etc.
- nucleic acid sequence is introduced into a cell is not essential to the invention, it may for instance be through integration in the genome or as an episomal plasmid.
- expression of the transgene may be restricted to a subset of the cells into which the nucleic acid sequence is inserted.
- transgene' is meant to include (1 ) a nucleic acid sequence that is not naturally found in the cell (i.e., a heterologous nucleic acid sequence); (2) a nucleic acid sequence that is a mutant form of a nucleic acid sequence naturally found in the cell into which it has been introduced ; (3) a nucleic acid sequence that serves to add additional copies of the same (i.e., homologous) or a similar nucleic acid sequence naturally occurring in the cell into which it has been introduced ; or (4) a silent naturally occurring or homologous nucleic acid sequence whose expression is induced in the cell into which it has been introduced.
- the transgene may also include a sequence encoding a leader peptide or signal sequence such that the transgene product will be secreted from the cell.
- the term 'vector' as used in the application refers to nucleic acid molecules, usually double- stranded DNA, which may have inserted into it another nucleic acid molecule (the insert nucleic acid molecule) such as, but not limited to, a cDNA molecule.
- the vector is used to transport the insert nucleic acid molecule into a suitable host cell.
- a vector may contain the necessary elements that permit transcribing the insert nucleic acid molecule, and, optionally, translating the transcript into a polypeptide.
- the insert nucleic acid molecule may be derived from the host cell, or may be derived from a different cell or organism. Once in the host cell, the vector can replicate independently of, or coincidental with, the host chromosomal DNA, and several copies of the vector and its inserted nucleic acid molecule may be generated.
- vector may thus also be defined as a gene delivery vehicle that facilitates gene transfer into a target cell.
- This definition includes both non-viral and viral vectors.
- Non-viral vectors include but are not limited to cationic lipids, liposomes, nanoparticles, PEG, PEI, etc.
- Viral vectors are derived from viruses including but not limited to: retrovirus, lentivirus, adeno- associated virus, adenovirus, herpesvirus, hepatitis virus or the like.
- viral vectors are replication-deficient as they have lost the ability to propagate in a given cell since viral genes essential for replication have been eliminated from the viral vector.
- some viral vectors can also be adapted to replicate specifically in a given cell, such as e.g. a cancer cell, and are typiclly used to trigger the (cancer) cell-specific (onco)lysis.
- Preferred vectors are derived from adeno-associated virus, adenovirus, retroviruses and Antiviruses.
- gene delivery systems can be used to combine viral and non- viral components, such as nanoparticles or virosomes (Yamada et al., 2003).
- Retroviruses and Antiviruses are RNA viruses that have the ability to insert their genes into host cell chromosomes after infection. Retroviral and lentiviral vectors have been developed that lack the genes encoding viral proteins, but retain the ability to infect cells and insert their genes into the chromosomes of the target cell (Miller, 1990; Naldini et al., 1996, VandenDriessche et al., 1999).
- lentiviral vectors can transduce both dividing and non-dividing cells whereas MLV-based retroviral vectors can only transduce dividing cells.
- Adenoviral vectors are designed to be administered directly to a living subject. Unlike retroviral vectors, most of the adenoviral vector genomes do not integrate into the chromosome of the host cell. Instead, genes introduced into cells using adenoviral vectors are maintained in the nucleus as an extrachromosomal element (episome) that persists for an extended period of time. Adenoviral vectors will transduce dividing and nondividing cells in many different tissues in vivo including airway epithelial cells, endothelial cells, hepatocytes and various tumors (Trapnell, 1993; Chuah et al., 2003). Another viral vector is derived from the herpes simplex virus, a large, double-stranded DNA virus. Recombinant forms of the vaccinia virus, another dsDNA virus, can accommodate large inserts and are generated by homologous recombination.
- Adeno-associated virus is a small ssDNA virus which infects humans and some other primate species, not known to cause disease and consequently causing only a very mild immune response. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell. These features make AAV a very attractive candidate for creating viral vectors for gene therapy, although the cloning capacity of the vector is relatively limited.
- the vector used is therefore derived from adeno-associated virus (i.e. AAV vector).
- AAV serotype 2 AAV serotype 5
- AAV serotype 8 AAV serotype 9
- all AAV serotypes are contemplated herein.
- the vector used is AAV serotype 9.
- the AAV vectors disclosed herein may be single-stranded (i.e. ssAAV vectors) or self- complementary (i.e. scAAV vectors).
- AAV vectors that comprise a FIX transgene as disclosed herein are preferably self-complementary
- AAV vectors that comprise a FVIII transgene as disclosed herein are preferably single-stranded.
- self-complementary AAV is meant herein a recombinant AAV-derived vector wherein the coding region has been designed to form an intra-molecular double-stranded DNA template.
- Gene therapy with adeno-associated viral vectors disclosed herein was shown to induce immune tolerance towards the transgene comprised in the vector.
- the vector is a transposon-based vector.
- said transposon-based vectors are preferably derived from Sleeping Beauty (SB) or PiggyBac (PB).
- SB Sleeping Beauty
- PB PiggyBac
- a preferred SB transposon has been described in Ivies et al. (1997).
- said transposon-based vectors comprise the nucleic acid expression cassettes disclosed herein.
- said transposon-based vectors are PiggyBac-based transposons. Such vectors are safe in that they do no enhance the tumorigenic risk. Furthermore, liver- directed gene therapy with these vectors was shown to induce immune tolerance towards the transgene, in particular hFIX, comprised in the vector.
- said PiggyBac-based vectors comprise micro inverted repeats, preferably inverted repeats having SEQ ID NO:29 and SEQ ID NO:30.
- micro inverted repeats is meant herein inverted repeats wherein the majority of the native sequence has been removed. Exemplary micro inverted repeats have been described in Meir et al. (201 1 .
- BMC Biotechnology 1 1 :28 are characterized by the sequences ttaaccctagaaagataatcatattgtgacgtacgttaaagataatcatgcgtaaaattgacgcatg (SEQ ID NO:29) and gcatgcgtcaattttacgcagactatctttctagggttaa (SEQ ID NO:30).
- Such micro inverted repeats advantageously increase the expression level of the transgene comprised in the vector.
- said transposon-based vector is a PiggyBac-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, the codon-optimized human FIX Padua mutant, and the bovine growth hormone polyadenylation signal, such as, e.g., the transposon defined by SEQ ID NO:15.
- said transposon-based vector comprises micro inverted repeats.
- said transposon-based vector is a PiggyBac-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, codon-optimized human FIX cDNA, and the bovine growth hormone polyadenylation signal, such as, e.g., the transposon defined by SEQ ID NO:14.
- said transposon-based vector comprises micro inverted repeats.
- said transposon-based vector is a PiggyBac-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, a codon-optimized human B domain deleted FVIII cDNA, and the SV40 polyadenylation signal, such as, e.g., the transposon defined by SEQ ID NO:13.
- said transposon-based vector comprises micro inverted repeats.
- said transposon-based vector is a Sleeping Beauty-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, codon-optimized human FIX cDNA, and the bovine growth hormone polyadenylation signal (Fig. 8I).
- the transposon-based vectors disclosed herein are preferably administered in combination with a vector encoding a transposase for gene therapy.
- the PiggyBac-derived transposon-based vector can be administered with wild-type PiggyBac transposase (Pbase) or mouse codon-optimized PiggyBac transposase (mPBase)
- said transposases are hyperactive transposases, such as, for example, SBmax transposase and hyperactive PB (hyPB) transposase containing seven amino acid substitutions (I30V, S103P, G165S, M282V, S509G, N538K, N570S) as described in Yusa et al. (201 1 ), which is specifically incorporated by reference herein.
- Transposon/transposase constructs can be delivered by hydrodynamic injection or using non-viral nanoparticles to transfect hepatocytes.
- nucleic acid regulatory elements can be used in gene therapy.
- Gene therapy protocols intended to achieve therapeutic gene product expression in target cells, in vitro, but also particularly in vivo, have been extensively described in the art. These include, but are not limited to, intramuscular injection of plasmid DNA (naked or in liposomes), interstitial injection, instillation in airways, application to endothelium, intrahepatic parenchyme, and intravenous or intra-arterial administration (e.g. intra-hepatic artery, intra-hepatic vein).
- Various devices have been developed for enhancing the availability of DNA to the target cell.
- a simple approach is to contact the target cell physically with catheters or implantable materials containing DNA.
- Another approach is to utilize needle-free, jet injection devices which project a column of liquid directly into the target tissue under high pressure.
- These delivery paradigms can also be used to deliver viral vectors.
- Another approach to targeted gene delivery is the use of molecular conjugates, which consist of protein or synthetic ligands to which a nucleic acid-or DNA- binding agent has been attached for the specific targeting of nucleic acids to cells (Cristiano et al., 1993).
- the use of the nucleic acid regulatory elements, nucleic acid expression cassettes or vectors as described herein is envisaged for gene therapy of liver cells.
- the use of the regulatory elements, expression cassettes or vectors is for gene therapy in vivo.
- the use is for a method of gene therapy to treat hemophilia, in particular to treat hemophilia B or hemophilia A.
- methods for expressing a protein in liver cells comprising the steps of introducing in liver cells the nucleic acid expression cassette (or a vector) as described herein and expressing the transgene protein product in the liver cells. These methods may be performed both in vitro and in vivo.
- Methods of gene therapy for a subject in need thereof comprising the steps of introducing in the liver of the subject a nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and expressing a therapeutic amount of the therapeutic protein in the liver.
- the method comprises the steps of introducing in the liver of the subject a vector comprising the nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and expressing a therapeutic amount of the therapeutic protein in the liver.
- the therapeutic protein encoded by the transgene in the nucleic acid expression cassette is factor IX
- the method is a method for treating hemophilia B. By expressing factor IX in the liver via gene therapy, hemophilia B can be treated (Snyder et al., 1999).
- the therapeutic protein encoded by the transgene in the nucleic acid expression cassette is factor VIII, and the method is a method for treating hemophilia A.
- the terms “subject” or “patient” are used interchangeably and refer to animals, preferably vertebrates, more preferably mammals, and specifically includes human patients and non-human mammals
- “mammalian” subjects include, but are not limited to, humans, domestic animals, commercial animals, farm animals, zoo animals, sport animals, pet and experimental animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates such as apes, monkeys, orang-utans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, hamsters and guinea pigs; and so on. Accordingly, "subject” or "patient” as
- the terms “treat” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of proliferative disease, e.g., cancer.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilised (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- a phrase such as "a subject in need of treatment” includes subjects, such as mammalian subjects, that would benefit from treatment of a given condition, such as, hemophilia B. Such subjects will typically include, without limitation, those that have been diagnosed with the condition, those prone to have or develop the said condition and/or those in whom the condition is to be prevented.
- terapéuticaally effective amount refers to an amount of a compound or pharmaceutical composition of the invention effective to treat a disease or disorder in a subject, i.e., to obtain a desired local or systemic effect and performance.
- the term implies that levels of factor IX in plasma equal to or higher than the therapeutic threshold concentration of 10mU/ml (milli-units per milliliter) plasma, 50mU/ml plasma, 100mU/ml plasma, 150mU/ml or 200mU/ml plasma in a subject can be obtained by transduction or transfection of the vector according to any one the embodiments described herein into a subject.
- the term implies that levels of factor VIII in plasma equal to or higher than the therapeutic threshold concentration of 10mU/ml (milli-units per milliliter) plasma, 50mU/ml plasma, 100mU/ml plasma, 150mU/ml plasma, 200mU/ml plasma or higher can be obtained by transduction or transfection of any of the vectors disclosed herein into a subject. Due to the very high efficiency of the vectors and nucleic acid expression cassettes disclosed herein, these high physiological levels of factor VIII in the subject can be obtained even by administering relatively low doses of vector.
- these terms refer to the quantity of compound or pharmaceutical composition according to the invention which is necessary to prevent, cure, ameliorate, or at least minimize the clinical impairment, symptoms, or complications associated with hemophilia, in particular hemophilia B or hemophila A, in either a single or multiple dose.
- the transduction of the vector according to any one of the embodiments defined herein into the subject can be done at a dose lower than 2x10 11 vg/kg (viral genomes per kilogram) to obtain a physiological factor IX level of 10mU/ml plasma or of 50mU/ml plasma in a subject.
- the transduction of the vector according to any one of the embodiments defined herein into the subject can be done at a dose lower than or equal to 6x10 11 vg/kg.
- the transduction of the vector according to any one of the embodiments defined herein into the subject can be done at a dose lower than or equal than 2x10 12 vg/kg.
- a level of factor IX of 200 mU/ml plasma or higher can be reached in a subject, when the transduction of the vector according to any one of the embodiments defined herein into the subject is done at a dose lower than or equal to 2x10 12 vg/kg.
- the transduction of the vector according to any one of the embodiments defined herein into the subject can be done at a dose lower than or equal to 2x10 12 vg/kg (viral genomes per kilogram), such as lower than or equal to 1 x10 12 vg/kg, 5x10 11 vg/kg, 2.5x10 11 vg/kg, 1 x10 11 vg/kg, 5x10 10 vg/kg, 1 x10 10 vg/kg, 5x10 9 vg/kg, or 1 x10 9 vg/kg preferably at a dose lower than or equal to 2.5x10 11 vg/kg, to obtain a physiological factor VIII level of 10 mU/ml plasma, 50 mU/ml plasma, 100 mU/ml plasma, 150 mU/ml plasma, 200 mU/ml plasma, or higher in a subject.
- 2x10 12 vg/kg viral genomes per kilogram
- efficacy of the treatment can, for example, be measured by assessing the hemophilia-caused bleeding in the subject.
- In vitro tests such as, but not limited to the in vitro actived partial thromboplastin time assay (APPT), test factor IX chromogenic activity assays, blood clotting times, factor IX or human factor VI ll-specific ELISAs are also available. Any other tests for assessing the efficacy of the treatment known in the art can of course be used.
- the compound or the pharmaceutical composition of the invention may be used alone or in combination with any of the know hemophilia therapies, such as the administration of recombinant or purified clotting factors.
- the compound or the pharmaceutical composition of the invention can thus be administered alone or in combination with one or more active compounds.
- the latter can be administered before, after or simultaneously with the administration of the said agent(s).
- a further object of the invention are pharmaceutical preparations which comprise a therapeutically effective amount of the expression vector of the invention as defined herein, and a pharmaceutically acceptable carrier, i.e., one or more pharmaceutically acceptable carrier substances and/or additives, e.g., buffers, carriers, excipients, stabilisers, etc.
- pharmaceutically acceptable as used herein is consistent with the art and means compatible with the other ingredients of a pharmaceutical composition and not deleterious to the recipient thereof.
- pharmaceutically acceptable salts as used herein means an inorganic acid addition salt such as hydrochloride, sulfate, and phosphate, or an organic acid addition salt such as acetate, maleate, fumarate, tartrate, and citrate.
- pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt.
- pharmaceutically acceptable ammonium salts are ammonium salt and tetramethylammonium salt.
- Examples of pharmaceutically acceptable organic amine addition salts are salts with morpholine and piperidine.
- Examples of pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.
- the pharmaceutical composition according to the invention can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of solutions for injection or infusion.
- suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or the inhalative administration in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods.
- the pharmaceutical composition can be prepared in a manner known per se to one of skill in the art.
- the expression vector according to the invention as defined herein, one or more solid or liquid pharmaceutically acceptable excipients and, if desired, in combination with other pharmaceutical active compounds are brought into a suitable administration form or dosage form which can then be used as a pharmaceutical in human medicine or veterinary medicine.
- a pharmaceutical composition comprising a nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition comprises a vector containing the nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and a pharmaceutically acceptable carrier.
- the transgene encodes factor IX and the pharmaceutical composition is for treating hemophilia B or the transgene encodes factor VIII and the pharmaceutical composition is for treating hemophilia A.
- nucleic acid expression cassette preferably hemophilia B or hemophilia A
- vector components as disclosed herein for the manufacture of these pharmaceutical compositions for use in treating hemophilia, preferably hemophilia B or hemophilia A, is also envisaged.
- Example 1 In vivo validation of liver-specific regulatory enhancer sequences expressing hyper-active FIX via AAV vector gene delivery.
- AAV-based vectors were constructed that express either the codon-optimized factor IX or the codon-optimized factor IX with the Padua R338L mutation from the TTRm promoter operably linked to the Serpin regulatory sequence.
- the Serpin regulatory sequence has been identified and described under patent application WO2009/130208.
- 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine (Gin), 100 lU/ml penicillin, 100 ⁇ g ml streptomycin and 10% heat- inactivated fetal bovine serum (FBS, Invitrogen, Merelbeke, Belgium).
- DMEM Dulbecco's modified Eagle's medium
- Gin L-glutamine
- penicillin 100 lU/ml
- streptomycin 100 lU/ml streptomycin
- FBS heat- inactivated fetal bovine serum
- the AAV serotype 9 viral vector was chosen to package the construct, known to be a promising vector for gene therapy (Vandendriessche et al. 2007).
- AAV vectors expressing human FIX were produced at high-titer by calcium phosphate transfection according to the manufacturer's instruction (Calcium phosphate transfection kit, Invitrogen) of 293 cells with AAV2-vector DNA (26 ⁇ g 10 cm dish), an adenoviral helper plasmid (52 ⁇ g 10 cm dish)and AAV helper plasmids expressing Rep2 and Cap9 (26 ⁇ g 10 cm dish) for production of AAV9 serotypes, as described in Gao et al. (2002), Mingozzi et al. (2003) and Gehrke (2003).
- Vector genome titers were determined by quantitative polymerase chain reaction (qPCR) using TaqMan® probes and primers specific for the polyadenylation signal (forward primer: 5'GCCTTCTAGTTGCCAGCCAT (SEQ ID No.3), probe: 5TGTTTGCCCCTCCCCCGTGC (SEQ ID No.4), reverse primer : 5'GGCACCTTCCAGGGTCAAG (SEQ ID No.5)).
- AAV vectors expressing either the human codon-optimized FIX cDNA (designated as AAV-co-hFIX in Fig. 2) or the human codon-optimized FIX-R338L cDNA (designated as AAV-co-padua-hFIX in Fig. 2) from a chimeric liver-specific promoter (SerpEnh/TTRm) were injected into FIX-deficient hemophilic mice that suffered from hemophilia B.
- a dose- response was observed and the AAV vector expressing the codon-optimized FIX-R338L yielded significantly higher FIX activity than the codon-optimzed FIX control without the hyper-activating mutation.
- the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector reached therapeutic FIX levels at a relatively low dose (>50% of normal FIX levels at 1x10 9 gc/mouse, >250% of normal FIX levels at 5x10 9 gc/mouse and >700% of normal FIX levels at 2x10 10 gc/mouse after 5 days), which underscores its potency.
- Example 2 Enhanced, liver-specific expression of FIX via AAV vector gene delivery. Materials and methods
- a FIX construct comprising human FIX cDNA (hFIX), was cloned downstream of a liver-specific minimal transthyretin (TTRm) promoter in an adeno-associated viral vector 9 (AAV9) backbone.
- TTRm liver-specific minimal transthyretin
- AAV9-SerpEnh-TTRm-hFIX which comprised an additional hepatocyte-specific regulatory element, namely the Serpin regulatory sequence ("Serp" or "SerpEnh”), upstream of the TTRm promoter.
- a minute virus of mice (MVM) intron was cloned in between the TTRm promoter and the hFIX transgene (AAV9-SerpEnh-TTRm-MVM-hFIX).
- the hFIX transgene was codon-optimized in order to augment the expression of the protein (AAV9-SerpEnh-TTRm-MVM-co-hFIX).
- a further improvement encompassed a mutation, namely the R338L, Padua mutation (Fig. 3C), of the co-hFIX fragment (AAV9-SerpEnh- TTRm-MVM-co-hFIX-R338L).
- Quantitative real-time PCR with SYBR® Green and primers for the bovine growth hormone polyadenylation sequence (bGHpolyA) was used to determine vector titers.
- the forward primer sequence was 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3).
- the reverse primer used was 5'-GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:5).
- known copy numbers (10 2 — 10 7 ) of the corresponding vector plasmids were used. Animal experiments and clotting assays
- FIX antigen concentration in citrated plasma was determined by enzyme-linked immunosorbent assay (ELISA) specific for hFIX antigen (Diagnostica Stago, France) using manufacturer's protocol.
- FIX activity was assessed using BIOPHEN Factor IX chromogenic assay (Hyphen BioMed, Neuville-sur-Oise, France) according to the manufacturer's protocol. For both assays, serially diluted hFIX standards were used for calibration.
- D-dimer levels were determined by ELISA, according to the manufacturers instructions (Hyphen Biomed, Neuville-sur-Oise, France).
- Tail-clipping assay was performed. Mice were anesthetized and tail was placed in pre- warmed 37°C normal saline solution for 2 minutes and subsequently cut at 2-3 mm diameter. Tail was then immediately placed in 37°C normal saline solution and monitored for bleeding and survival.
- Immunizations were carried out by subcutaneous injection of 5 ⁇ g of recombinant human (rh)FIX protein (BeneFix, Pfizer, Italy) in incomplete Freund's adjuvant (I FA) (Sigma- Aldrich, USA). Briefly, 96-well microtiter plates were coated with hFIX ( ⁇ g/ml) and serially diluted standards made of purified mouse IgG (Invitrogen, Europe). The plate was incubated overnight at 4° C. On day 2, the samples of mouse plasma were diluted in dilution buffer, loaded on the pre-coated plates and incubated overnight at 4°C.
- mice were obtained from mice injected with AAV9-SerpEnh- TTRm-MVM-co-hFIX-R338L.
- the plate was then incubated with horseradish peroxidase (HRP)-goat anti-mouse IgG (Invitrogen, Europe) secondary antibody.
- HRP horseradish peroxidase
- Anti- hFIX antibody levels were measured following incubation with detection buffer constituting 12ml 0.01 M sodium citrate, 12mg o-phenylenediamine and 2.5 ⁇ hydrogen peroxide (Invitrogen, Europe).
- the chromogenic reaction was monitored by determining the absorbance at 450 nm.
- Genomic DNA was extracted from different tissues using the DNeasy Blood & Tissue Kit (Qiagen, Chatsworth, CA, USA). 100ng DNA was analyzed using qPCR ABI Prism 7900HT (Applied Biosystems, Foster City/CA, USA) with bGHPolyA specific primers 5'- GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3) (forward) and 5 - GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:4) (Reverse). To generate standard curves, known copy numbers of the corresponding vector plasmid was used.
- RNA from different organs was reverse transcribed to cDNA.
- cDNA was then analyzed by qPCR ABI Prism 7900HT (Applied Biosystems, Foster City/CA, USA) using bGHPolyA specific primers 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3) (forward) and 5'- GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:4) (Reverse).
- GPDH glyceraldehyde-3-phosphate dehydrogenase
- Figure 4 shows that administration of the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector to hemophilia B mice provides for significantly higher FIX levels and activity compared to the AAV9-SerpEnh-TTRm-MVM-co-hFIX vector.
- the FIX response was dose-dependent.
- Therapeutic FIX levels could be attained at relatively low vector doses of 1 x10 9 vgc/mouse, 5x10 9 vgc/mouse, and 2x10 10 vgc/mouse. Furthermore, these vector doses are safe as no thrombolysis was observed (Fig. 4J).
- Figure 5 shows that FIX was specifically expressed in the liver (Fig. 5 C-D), despite transduction of the vector in other organs (Fig. 5 A-B).
- Example 3 Liver-specific expression of FVIII via AAV vector gene delivery.
- AAV-based vectors were constructed that express a codon-optimized B domain-deleted human coagulation factor VIII (hFVIIIcopt) cDNA (Ward et al., 201 1 ) from the minimal TTR (TTRm) promoter operably linked to the nucleic acid regulatory element Serpin enhancer ("Serp" or "SerpEnh”) described in WO 2009/130208, which is specifically incorporated by reference herein.
- TTRm minimal TTR
- Serpin enhancer Serpin enhancer
- the codon-optimized B domain-deleted human FVIII cDNA was PCR amplified and subcloned into a pGEM-T easy plasmid (Promega, Belgium) and after restriction with Spel-BamHI, the FVIII cDNA was cloned into the Nhel-Bglll restricted pAAV-SerpEnh-TTRm vector to generate AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt- SV40pA (also indicated as AAVss-SerpTTRm-MVM-FVIIIcopt-sv40pA herein).
- This vector also contained a small intron from minute virus of mouse (MVM) to boost FVIII expression levels.
- primers binding the SV40 polyA region were used, including 5'- TGATGCTATTGCTTTATTTGTAACC-3' (SEQ ID NO:20) as forward primer, 5'- CCTGAACCTGAAACATAAAATGA-3' (SEQ ID NO:21 ) as reverse primer and 5'-FAM- AGCTGCAATAAACAAGTTAACAACAACAATTGCA-TAMRA-3' (SEQ ID NO:22)as probe. Titers were achieved in the normal range of 2-5x10 12 vg/ml.
- the AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vectors were injected intravenously into adult male SCID mice (CB17/lcrTac/Prkdc scid) at a dose of 5x10 9 vg/mouse or 2.5x 10 11 vg/kg.
- FVIII antigen levels were assayed in citrated mouse plasma using a hFVIII-specific enzyme-linked immunosorbent assay (ELISA) (Asserachrom® VIII:Ag, Diagnostica Stago, France), as per the manufacturer's instructions. Samples were diluted in sample diluent provided and analyzed in triplicate. Standard curves in percentage FVIII antigen activity were constructed by diluting normal control plasma. In brief, 200 ml diluted samples and standards were pipetted into the wells of the strips pre-coated with mouse monoclonal anti-human FVIII Fab fragments and incubated for 2 hours at room temperature for antigen immobilization.
- ELISA enzyme-linked immunosorbent assay
- the wells were then washed with the wash buffer for 5 times before adding 200 ml mouse monoclonal anti-hFVIII antibody coupled with peroxidase for immobilization of immunoconjugate. After incubation for 2 hr at room temperature and washing, 200 ml of TMB substrate was added to the wells for color development. This mixture was incubated at room temperature for exactly 5 minutes. The reaction was then stopped by 50ml 1 M H 2 S0 4 and then read at 450 nm within 1 h.
- High-titer AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vectors expressing a codon- optimized B-domain deleted human FVIII cDNA (hFVIIIcopt) from a liver-specific promoter (TTRm) operably linked to a regulatory element ("Serp” or "SerpEnh”) could be produced with a total insert size of 4913 bp (excluding ITR) (Fig. 6).
- Intravenous injection of a very low vector dose (5x10 9 vg/mouse) resulted in therapeutic FVIII levels approximating 421 .8 ⁇ 4.9 ng/ml (i.e.
- AAV9ss- SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vector is the most robust AAV-FVIII vector design to date.
- Example 4 Enhanced, liver-specific expression of FVIII and FIX via transposon- based gene delivery.
- the codon-optimized hyperactive PB transposase (huPB) was cloned into pcDNA3 and expressed from the CAG promoter (Fig. 8A,B).
- the hyperactive SBmax transposase was cloned into pcDNA3 and expressed from the CAG promoter (Fig. 8K,L).
- a codon- optimized B-domain deleted FVIII (hFVIIIcopt), described as SQ FVIII (co) in Ward et al.
- PB_micro_T_NoJns_TTRminSerpMVM_hFIXco_bghpA (Fig. 8E,F) and PB_micro_T_NoJns_TTRminSerpMVM_hFIXco_Padua_bghpA (Fig. 8G,H), respectively.
- the human codon-optimized FIX cDNA was cloned by conventional cloning techniques into an SB-based vector to generate pT2BH_TTRminSerpMVM_hFIXco_bghpA (Fig. 8I,J).
- the transgenes were expressed from a liver-specific minimal transthyretin (TTRm) promoter along with the Serpin enhancer ("Serp” or “SerpEnh”).
- TTRm liver-specific minimal transthyretin
- Serpin enhancer ("Serp” or "SerpEnh”
- the contructs also contained a mouse mini-intron (MVM) and a polyadenylation site.
- VMM mouse mini-intron
- the recombinant clones were verified by restriction analysis and sequencing.
- the different FVIII-transposons and matching plasmids encoding the cognate hyperactive transposases were purified by ion exchange chromatography and transfected by hydrodynamic transfection at varying transposon/transposase ratios and concentrations into adult mice. Controls without transposase were employed.
- the FIX expression was monitored by ELISA or using chromogenic activity assays in hemophilia B mice. FVIII expression in SCID mice was assessed using a human FVIII-specific ELISA.
- Fig. 10 demonstrates that the use of the liver-specific Serpin enhancer ("Serp” or “SerpEnh”) in conjunction with codon-optimized B-domain deleted FVIII (hFVIIIcopt), and the hyperactive hyPB system resulted in robust, stable gene transfer efficiencies in hepatocytes, yielding high unprecedented expression levels of FVIII. Conversely, in the absence of the hyperactive hyPB transposase, expression declined gradually to basal levels. This confirms that stable genomic integration by transposition is required for stable hepatic FVIII gene expression.
- Serpin codon-optimized B-domain deleted FVIII
- SB Sleeping Beauty (SB) transposon
- PB PiggyBac
- P B_m i cro_T_N oj n s_Se rpTTrm i n M V M_h F I Xco_B G H pA) was compared side by side with the PiggyBac (PB) transposon ( P B_m i cro_T_N oj n s_Se rpTTrm i n M V M_h F I Xco_B G H pA)) in immunodeficient NOD SCID mice using two different doses as indicated (Fig. 1 1 ).
- FIX ELISA was performed to determine the amount of FIX expression.
- mice were injected repeatedly with the carcinogen ⁇ , ⁇ -diethylnitrosamine (DEN) and developed hepatocellular carcinoma.
- DEN carcinogen ⁇ , ⁇ -diethylnitrosamine
- the tumor burden was assessed 36 weeks post-DEN injection.
- PB transposition in itself does not significantly increase tumorigenicity, even in an HCC tumor-prone mouse model, which supports its safety.
- Example 5 Enhanced expression of FVIII and FIX by cloning the MVM intron into the nucleic acid expression cassette.
- a piggyBac transposon plasmid was constructed that comprises human FIX cDNA cloned downstream of a liver-specific minimal transthyretin (TTRmin) promoter operably linked to the Serpin regulatory sequence ("Serp” or “SerpEnh” or “HSH8").
- TTRmin liver-specific minimal transthyretin
- the bovine growth hormone poly A (bghpA) was provided as a transcription termination signal.
- Human FIX cDNA comprises a truncated 1 .4 kb intron A between exons 1 and the following exons 2- 8.
- pB_hFIXIA A schematic representation of said transposon, denoted as pB_hFIXIA, is shown in Figure 12A.
- a piggyBac transposon plasmid was constructed that contains a synthetic codon- optimized human FIX cDNA without intron A. Said codon-optimized hFIX cDNA was cloned downstream of a liver-specific minimal transthyretin (TTRmin) promoter operably linked to the Serpin regulatory sequence ("Serp” or “SerpEnh” or “HSH8"). A minute virus of mice (MVM) intron was cloned between the TTRmin promoter and the hFIXco transgene. The bovine growth hormone poly A (bghpA) was provided as a transcription termination signal. A schematic representation of said transposon, denoted as pB_hFIXco, is shown in Figure 12B. The plasmids were constructed by conventional cloning and DNA synthesis.
- Hemophilia B mice were hydrodynamically injected with 10 ⁇ g transposon plasmid and 2 ⁇ g of mouse transposase plasmid mpBase (Fig. 12C) or empty control plasmid (Fig. 12D) diluted in 2 ml of PBS into the tail vein. Typically, the injection took less than 10 s for each mouse. Determination of hFIX levels and activity occurred as described in Example 2.
- Genomic DNA was extracted from frozen liver samples according to DNeasy Blood & Tissue Kit protocol (Qiagen, Chatsworth, CA, USA). RNase A (Qiagen, Chatsworth, CA, USA) treatment was carried out to eliminate carry-over RNA.
- Transposon copy numbers were quantified by qPCR using a primer set against a specific region common to both transposon constructs using forward primer 5'- AACAGGGGCTAAGTCCACAC -3' (SEQ ID NO: 25) and reverse primer 5'- GAGCGAGTGTTCCGATACTCT -3' (SEQ ID NO: 26).
- the following primer set was used: forward primer 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3), reverse primer 5'- GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:4).
- the hFIX mRNA levels were normalized using a primer set against the mRNA of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (mGAPDH) which is uniformly and constantly expressed in all samples (i.e. forward primer 5'- ATCAAGAAGGTGGTGAAGCAGGCA -3' (SEQ ID NO:27) and reverse primer 5 - TGGAAGAGTGGGAGTTGCTGTTGA -3' (SEQ ID NO:28)).
- mGAPDH housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
- RNA samples were amplified with and without reverse transcriptase to exclude genomic DNA amplification.
- the 2 _AACt relative quantification method was used to determine the relative changes in hFIX mRNA expression level.
- the ACt was calculated by subtracting the Ct of mGAPDH mRNA from the Ct of the hFIX mRNA (Ct h Fix - C ⁇ .GAPDH)-
- the AACt was calculated by subtracting the ACt of the reference sample (highest Ct) from the ACt of each sample (ACt samp ie - ACtreference)- Fold-change was determined by using the equation 2 _ ⁇ .
- hFIX expression and activity is transient and gradually declines to basal levels in mice that were co-injected with the empty control plasmid
- Fig. 12E pB_hFIXIA + empty plasmid: 46 ⁇ 13 ng/ml hFIX, 0,87 ⁇ 0,2% normal clotting activity
- Fig. 12F pB_hFIXco + empty plasmid: 48 ⁇ 22 ng/ml hFIX, 0,97 ⁇ 0,49% normal clotting activity.
- the transposon plasmid comprising the MVM intron yielded significantly higher hFIX levels and activity as compared to the plasmid without MVM intron when co-delivered with the mouse transposase plasmid (Fig. 12E,F).
- the increase in hFIX protein levels was consistent with a more than 57-fold increase in hFIX mRNA levels when comparing the transposon with and without the MVM intron (Fig. 12 H), although the transposon copies per genome content were similar in the liver of mice that were injected with pB hFIXIA and pB hFIXco (Fig. 12G).
- Example 6 Comparison of expression cassettes comprising a FVIII transgene.
- Example 3 The AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid of Example 3 was compared to:
- AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA plasmid (c) was constructed by excising the Serpin enhancer from AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid.
- mice were hydrodynamically injected with 2 ⁇ g or 5 ⁇ g of the plasmid DNA diluted in 2 ml of phosphate buffered saline (PBS) and injected into the tail vein. Typically, the injection took less than 10 s for each mouse.
- FVIII expression analysis was carried out as described in Example 3. Results
- AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA (c) and AAV9ss-SerpEnh-TTRm-MVM- hFVIIIcopt-SV40pA (d) constructs were hydrodynamically injected in mice at 2 ⁇ g and 5 ⁇ g DNA, and human FVIII levels were measured 1 , 2 and 6 days post-transfection.
- the effect of cloning the Serpin enhancer into the expression cassette on hFVIII levels can be calculated by dividing the hFVIII levels measured in mice injected with construct (d) by the levels measured in mice injected with construct (c). 3- to 6-fold higher hFVIII levels can be obtained by cloning the Serpin enhancer into the expression cassette (Table 2).
- the codon-optimized B domain-deleted human coagulation factor VIII (hFVIIIcopt) cDNA was reported to achieve 29- to 44-fold increase in expression (Ward et al. 201 1 ).
- mice that are hydrodynamically injected with AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA construct we can further predict the hFVIII levels in mice that are hydrodynamically injected with AAV9ss-TTRm-MVM-hFVIII- SV40pA construct (a) by dividing said predicted hFVIII levels by the calculated effect of cloning the Serpin enhancer into the expression cassette on hFVIII levels.
- mice hydrodynamically injected with the different constructs a-d are summarized in Table 3 and Figures 13A and 13B.
- mice hydrodynamically injected with 2 or 5 ⁇ g of plasmids (a) AAV9ss-TTRm-MVM-h FVI I l-SV40pA, (b) AAV9ss-SerpEnh-TTRm-MVM-h FVI I l-SV40pA, (c) AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA, and (d) AAV9ss-SerpEnh-TTRm-MVM- hFVIIIcopt-SV40pA.
- Predicted level Predicted level:
- Table 4 Comparison of hFVI II levels induced by AAV9ss-SerpEnh-TTRm-MVM- hFVI IIcopt-SV40pA construct (d) as compared to the levels induced by (b) AAV9ss- SerpEnh-TTRm-MVM-hFVI I I-SV40pA construct and (c) AAV9ss-TTRm-MVM-hFVI I Icopt- SV40pA construct, and as compared to the levels induced by (a) AAV9ss-TTRm-MVM- hFVII I-SV40pA construct.
- Example 7 Comparison of expression cassettes comprising a FIX transgene.
- AAV-based plasmids comprising a FIX transgene were constructed as described in Example 2.
- FIX knockout mice were hydrodynamically injected with 2 ⁇ g of each of the following FIX plasmids diluted in 2 ml of phosphate buffered saline (PBS) into the tail vein:
- PBS phosphate buffered saline
- FIX activity was determined as described in Example 2.
- FIX activity as measured in the different mice is summarized in Table 5.
- mice hydrodynamically injected with 2 of (a) AAVsc-TTRm-MVM-hFIX-pA plasmid, (b) AAVsc-SerpEnh-TTRm-MVM-hFIX- pA plasmid, (c) AAVsc-TTRm-MVM-hFIXco-pA plasmid, (d) AAVsc-SerpEnh-TTRm-MVM- hFIXco-pA plasmid, (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid, and (f) AAVsc- SerpEnh-TTRm-MVM-hFIXcoPadua-pA plasmid.
- hFIX activity in mice hydrodynamically injected with (f) AAVsc-SerpEnh-TTRm- MVM-hFIXcoPadua-pA plasmid was compared versus hFIX activity in mice hydrodynamically injected with (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA plasmid and (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid (Table 6, Figures 14C and 14D).
- the combination of the Serpin enhancer and the Padua mutation provides for a synergistic effect on hFIX activity.
- the combination of the Serpin enhancer with codon-optimized transgene encoding hFIX containing the Padua mutation shows synergy on hFIX activity, as revealed by comparing hFIX activity in mice injected with (f) AAVsc-SerpEnh-TTRm-MVM- hFIXcoPadua-pA plasmid versus hFIX activity in mice injected with (b) AAVsc-SerpEnh- TTRm-MVM-hFIX-pA plasmid, and (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid.
- Table 6 Comparison of hFIX activity induced by the different FIX plasmids: (a) AAVsc- TTRm-MVM-hFIX-pA plasmid, (b) AAVsc-SerpEnh-TTRm-MVM-hFIX-pA plasmid, (c) AAVsc-TTRm-MVM-hFIXco-pA plasmid, (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA plasmid, (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid, and (f) AAVsc-SerpEnh- TTRm-MVM-hFIXcoPadua-pA plasmid.
- Example 8 Evaluation of the piggyBac transposon system.
- pB_hFIXIA (Fig. 12A) and pB_hFIXco (Fig. 12B) plasmids were constructed as described in Example 5.
- a terminal inverted repeat of pB_hFIXco (I R w t) was replaced by a terminal inverted repeat containing T53C and C136T point mutation (IR mu ti6) to generate pB_hFIXco/IR mu ti6 (Fig. 15A).
- pB_hFIX-R338L plasmid containing hyper-functional, codon-optimized hFIX transgene with Padua mutation was constructed by site-directed mutagenesis using pB_hFIXco/IR miC ro as template.
- hFIX antigen levels and activity and antibodies directed against hFIX were analyzed as described in Example 2.
- a tail-clipping assay was used on hemophilic mice to assess phenotypic correction of the bleeding phenotype. Briefly, the tails of mice were transected (1 cm from the end) and mice were monitored for clotting and survival. Tail clip was performed on immobilized mice, allowing continuous blood collection at room temperature and total blood volume, bleeding time and survival rate were monitored.
- a tail-clip assay showed that the bleeding diathesis of hemophilia B mice transfected with pB-hFIXIA or pB-hFIXco and plasmid encoding mPBase was phenotypically corrected 1 year post-transfection (Table 7). Bleeding time and volume were lower in mice transfected with plasmid comprising codon-optimized hFIX transgene and MVM intron compared to mice transfected with wild-type hFIX transgene. Table 7: Phenotypic correction of murine hemophilia B following tail clipping 48 weeks after gene transfer.
- hyPBase hyperactive PB transposase
- Fig. 15D hyperactive PB transposase
- This hyPBase contained several mutated residues compared to the mouse codon-usage optimized mPBase (compare Fig. 15D with 12C).
- Liver-directed hydrodynamic transfection of immune deficient SCID mice with 500 ng of pB-hFIXco transposon along with 1000 ng hyPB resulted in stable supra-physiologic hFIX levels corresponding to 200% of normal hFIX levels (Fig. 15F).
- FIX levels were significantly higher (p ⁇ 0.001 ) than what could be achieved with the original mPB transposase.
- liver-directed transfection of SCID mice with 50 ng of pB-hFIXco transposon plasmid along with 100 ng hyPB resulted in a dose-dependent effect yielding therapeutic hFIX levels corresponding to 20% of normal levels. This represented a significant 20-fold increase (p ⁇ 0.001 ) in FIX levels compared to when the mPB transposase was used (Fig 15G).
- mice were hydrodynamically injected with pB-hFIXco (Fig.12B), pB- hFIXco/IR mut i6. (Fig. 15A) or B-hF ⁇ Xco/ ⁇ R micro (Fig. 15B) along with hyPBase.
- pB-hFIXco Fig.12B
- pB- hFIXco/IR mut i6 Fig. 15A
- B-hF ⁇ Xco/ ⁇ R micro Fig. 15B
- Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103, 804-10.
- a microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 1 10, 4144-52.
- Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther. 2009 May;20(5):479-85.
- FIELDS PA ARRUDA VR
- ARMSTRONG E KIRK CHU
- MINGOZZI F. HAGSTROM
- J. HERZOG R
- HIGH KA. 1999 .
- Targeting lentiviral vector expression to hepatocytes limits transgene- specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103, 3700-9.
- Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 4, 192-200.
- Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest. 19, 2086-99.
- a microRNA- regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Mol Ther. 19, 723-30.
- McCARTY DM, MONAHAN PE, and SAMULSKI RJ. (2001 ).
- Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.
- Adeno-associated virus terminal repeat (TR) mutant generates self- complementary vectors to overcome the rate-limiting step to transduction in vivo.
- MI LLER AD (1990) Retrovirus packaging cells. Hum Gene Ther. Spring;1 (1 ):5-14.
- VANDENDRIESSCHE T VANSLEMBROUCK V, GOOVAERTS I, ZWINNEN H, VANDERHAEGHEN ML, COLLEN D, and CHUAH MK. (1999). Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VII l-deficient mice. Proc Natl Acad Sci USA. 96, 10379-84.
- Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100, 813-22.
- VANDENDRIESSCHE T THORREZ L, ACOSTA-SANCHEZ A
- PETRUS I WANG L, MA L, DE WAELE L, IWASAKI Y, GILLIJNS V, WILSON JM, COLLEN D, and CHUAH MK.
- VANDENDRIESSCHE T IVICS Z, IZSVAK Z, and CHUAH MK. (2009). Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 1 14, 1461 -8.
- WANG L WANG L, TAKABE K, BIDLINGMAIER SM, ILL CR, and VERMA IM. (1999). Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 96, 3906-3910. WANG L, NICHOLS TC, READ MS, BELLINGER DA, and VERMA IM. (2000). Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 1 , 154-158.
- Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 101 , 3924 - 3932.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015538476A JP6454643B2 (en) | 2012-10-26 | 2013-10-25 | Vectors and methods and uses for liver-directed gene therapy for hemophilia |
US14/438,571 US10398787B2 (en) | 2012-10-26 | 2013-10-25 | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
CA2888931A CA2888931C (en) | 2012-10-26 | 2013-10-25 | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
EP13789223.8A EP2911687B1 (en) | 2012-10-26 | 2013-10-25 | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
DK13789223.8T DK2911687T3 (en) | 2012-10-26 | 2013-10-25 | Vector for liver-targeted gene therapy of hemophilia and methods and use thereof |
EP19156735.3A EP3513802B1 (en) | 2012-10-26 | 2013-10-25 | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
AU2013336601A AU2013336601B2 (en) | 2012-10-26 | 2013-10-25 | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
US16/229,491 US11419950B2 (en) | 2012-10-26 | 2018-12-21 | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
US17/812,951 US20230022390A1 (en) | 2012-10-26 | 2022-07-15 | Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2012/071297 | 2012-10-26 | ||
PCT/EP2012/071297 WO2014063753A1 (en) | 2012-10-26 | 2012-10-26 | Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof |
EP2013064054 | 2013-07-03 | ||
EPPCT/EP2013/064054 | 2013-07-03 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19156735.3A Previously-Filed-Application EP3513802B1 (en) | 2012-10-26 | 2013-10-25 | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
US14/438,571 A-371-Of-International US10398787B2 (en) | 2012-10-26 | 2013-10-25 | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
US16/229,491 Continuation US11419950B2 (en) | 2012-10-26 | 2018-12-21 | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014064277A1 true WO2014064277A1 (en) | 2014-05-01 |
Family
ID=49554217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/072450 WO2014064277A1 (en) | 2012-10-26 | 2013-10-25 | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
Country Status (7)
Country | Link |
---|---|
US (2) | US11419950B2 (en) |
EP (1) | EP2911687B1 (en) |
JP (1) | JP6454643B2 (en) |
AU (1) | AU2013336601B2 (en) |
CA (1) | CA2888931C (en) |
DK (1) | DK2911687T3 (en) |
WO (1) | WO2014064277A1 (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016127057A1 (en) | 2015-02-06 | 2016-08-11 | The University Of North Carolina At Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
WO2016075473A3 (en) * | 2014-11-12 | 2016-08-18 | Ucl Business Plc | Factor ix gene therapy |
WO2016146757A1 (en) | 2015-03-17 | 2016-09-22 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for fviii and fix |
WO2016183422A1 (en) | 2015-05-14 | 2016-11-17 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
WO2016164609A3 (en) * | 2015-04-08 | 2016-12-15 | Genzyme Corporation | Production of oversized adeno-associated vectors |
US20170087219A1 (en) * | 2015-09-24 | 2017-03-30 | Biomarin Pharmaceutical Inc. | Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same |
WO2017074526A1 (en) * | 2015-10-28 | 2017-05-04 | Sangamo Biosciences, Inc. | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
WO2017083764A1 (en) | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
WO2017083762A1 (en) | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
JP2017518082A (en) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス, インコーポレイテッド | Methods and uses for directing proteins to specific loci in the genome |
KR20170084012A (en) * | 2014-08-13 | 2017-07-19 | 더 칠드런스 호스피탈 오브 필라델피아 | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
WO2017180857A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia a |
US10058624B2 (en) | 2015-04-16 | 2018-08-28 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
WO2018162748A1 (en) | 2017-03-10 | 2018-09-13 | Genethon | Treatment of glycogen storage disease iii |
US10081661B2 (en) | 2013-12-09 | 2018-09-25 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
WO2018178067A1 (en) | 2017-03-27 | 2018-10-04 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
WO2018217731A1 (en) | 2017-05-22 | 2018-11-29 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b |
JP2019527033A (en) * | 2016-05-16 | 2019-09-26 | バクスアルタ インコーポレイテッド | Anti-factor IX Padua antibody |
WO2020018419A1 (en) | 2018-07-16 | 2020-01-23 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
WO2020084162A1 (en) | 2018-10-26 | 2020-04-30 | Vrije Universiteit Brussel | Liver-specific nucleic acid regulatory elements and methods and use thereof |
WO2020084161A1 (en) | 2018-10-26 | 2020-04-30 | Vrije Universiteit Brussel | New tools for improving gene therapy and use thereof |
WO2020150375A1 (en) | 2019-01-16 | 2020-07-23 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
WO2020160303A1 (en) | 2019-02-01 | 2020-08-06 | Baxalta Incorporated | Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression |
US10844361B2 (en) | 2012-11-16 | 2020-11-24 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
US10960085B2 (en) | 2016-09-07 | 2021-03-30 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
WO2021119357A2 (en) | 2019-12-12 | 2021-06-17 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
US11191847B2 (en) | 2016-04-15 | 2021-12-07 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia B |
US11230720B2 (en) | 2015-10-14 | 2022-01-25 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
WO2022061014A1 (en) * | 2020-09-16 | 2022-03-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
WO2022077806A1 (en) * | 2020-10-16 | 2022-04-21 | 广州吉妮欧生物科技有限公司 | Sars-cov-2 pseudovirus mouse in-vivo packaging system and preparation method therefor |
RU2774874C2 (en) * | 2015-10-28 | 2022-06-23 | Сангамо Терапьютикс, Инк. | Liver-specific structures, expression cassettes of factor viii and their application methods |
US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
WO2022264040A1 (en) | 2021-06-14 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
WO2023006890A1 (en) | 2021-07-28 | 2023-02-02 | Vrije Universiteit Brussel | Improving the efficacy of muscle-targeted gene therapy |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
US11952585B2 (en) | 2020-01-13 | 2024-04-09 | Homology Medicines, Inc. | Methods of treating phenylketonuria |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10398787B2 (en) | 2012-10-26 | 2019-09-03 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
US11633504B2 (en) | 2017-05-09 | 2023-04-25 | Emory University | Nucleic acids encoding clotting factor variants and their use |
EP3652326A1 (en) * | 2017-07-10 | 2020-05-20 | uniQure IP B.V. | Means and methods for aav gene therapy in humans |
US20240182921A1 (en) * | 2021-03-04 | 2024-06-06 | Poseida Therapeutics, Inc. | Compositions and methods for the treatment of hemophilia |
WO2024074143A1 (en) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Construct for enhancing gene expression |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009130208A1 (en) * | 2008-04-22 | 2009-10-29 | Vib Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
WO2011005968A1 (en) * | 2009-07-08 | 2011-01-13 | Ucl Business Plc | Codon-optimized factor vi i i variants and synthetic liver-specific promoter |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200560B1 (en) * | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
JP2003511082A (en) * | 1999-10-12 | 2003-03-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Adeno-associated virus vector encoding factor VIII and uses thereof |
WO2007149852A2 (en) * | 2006-06-19 | 2007-12-27 | Asklepios Biopharmaceutical, Inc. | Modified factor viii and factor ix genes and vectors for gene therapy |
WO2009071679A1 (en) * | 2007-12-05 | 2009-06-11 | Vib Vzw | Novel aav vector and uses thereof |
ES2524974T3 (en) * | 2009-06-25 | 2014-12-16 | The University Of North Carolina At Chapel Hill | Chimeric Factor VII molecules |
TWI557135B (en) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | Modified factor ix polypeptides and uses thereof |
US10398787B2 (en) * | 2012-10-26 | 2019-09-03 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
-
2013
- 2013-10-25 DK DK13789223.8T patent/DK2911687T3/en active
- 2013-10-25 AU AU2013336601A patent/AU2013336601B2/en not_active Ceased
- 2013-10-25 WO PCT/EP2013/072450 patent/WO2014064277A1/en active Application Filing
- 2013-10-25 CA CA2888931A patent/CA2888931C/en active Active
- 2013-10-25 JP JP2015538476A patent/JP6454643B2/en active Active
- 2013-10-25 EP EP13789223.8A patent/EP2911687B1/en active Active
-
2018
- 2018-12-21 US US16/229,491 patent/US11419950B2/en active Active
-
2022
- 2022-07-15 US US17/812,951 patent/US20230022390A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009130208A1 (en) * | 2008-04-22 | 2009-10-29 | Vib Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
WO2011005968A1 (en) * | 2009-07-08 | 2011-01-13 | Ucl Business Plc | Codon-optimized factor vi i i variants and synthetic liver-specific promoter |
Non-Patent Citations (3)
Title |
---|
A. CANTORE ET AL: "Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice", BLOOD, vol. 120, no. 23, 4 October 2012 (2012-10-04), pages 4517 - 4520, XP055050690, ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-432591 * |
SCHUETTRUMPF JOERG ET AL: "Factor IX variants improve gene therapy efficacy for hemophilia B", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 6, 15 March 2005 (2005-03-15), pages 2316 - 2323, XP002555907, ISSN: 0006-4971, [retrieved on 20041118], DOI: 10.1182/BLOOD-2004-08-2990 * |
ZHIJIAN WU ET AL: "Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose", MOLECULAR THERAPY, vol. 16, no. 2, 1 February 2008 (2008-02-01), pages 280 - 289, XP055097643, ISSN: 1525-0016, DOI: 10.1038/sj.mt.6300355 * |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10844361B2 (en) | 2012-11-16 | 2020-11-24 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
US11634463B2 (en) | 2013-12-09 | 2023-04-25 | Sangamo Therapeutics, Inc. | Methods and compositions for treating hemophilia |
US10968261B2 (en) | 2013-12-09 | 2021-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
US10081661B2 (en) | 2013-12-09 | 2018-09-25 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
JP2017518082A (en) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス, インコーポレイテッド | Methods and uses for directing proteins to specific loci in the genome |
KR20170084012A (en) * | 2014-08-13 | 2017-07-19 | 더 칠드런스 호스피탈 오브 필라델피아 | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
US11014975B2 (en) | 2014-08-13 | 2021-05-25 | The Children's Hospital Of Philadelphia | Expression cassette for packaging and expression of variant factor VIII for the treatment of hemostasis disorders |
AU2015301598B2 (en) * | 2014-08-13 | 2020-07-16 | Liron Elkouby | An improved expression cassette for packaging and expression of variant Factor VIII for the treatment of hemostasis disorders |
EP3180022A4 (en) * | 2014-08-13 | 2019-02-20 | The Children's Hospital of Philadelphia | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
KR102665348B1 (en) * | 2014-08-13 | 2024-05-16 | 더 칠드런스 호스피탈 오브 필라델피아 | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
JP2021003120A (en) * | 2014-08-13 | 2021-01-14 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Improved expression cassette for genome-packaging and expression of variant factor viii for treatment of hemostasis disorders |
JP7237903B2 (en) | 2014-08-13 | 2023-03-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Improved expression cassette for genomic integration and expression of mutant factor VIII to treat hemostatic disease |
JP2018506261A (en) * | 2014-08-13 | 2018-03-08 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Improved expression cassette for genomic integration and expression of mutation factor VIII for treating hemostatic diseases |
WO2016075473A3 (en) * | 2014-11-12 | 2016-08-18 | Ucl Business Plc | Factor ix gene therapy |
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
US11344608B2 (en) | 2014-11-12 | 2022-05-31 | Ucl Business Ltd | Factor IX gene therapy |
CN107531774A (en) * | 2015-02-06 | 2018-01-02 | 北卡罗来纳大学查珀尔希尔分校 | Mankind's Coagulation factor VIII gene expression cassette of optimization and application thereof |
EP3611186A1 (en) * | 2015-02-06 | 2020-02-19 | The University of North Carolina at Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
US10308705B2 (en) | 2015-02-06 | 2019-06-04 | The University Of North Carolina At Chapel Hill | Optimized human clotting factor VIII gene expression cassettes and their use |
CN107531774B (en) * | 2015-02-06 | 2021-12-14 | 北卡罗来纳大学查珀尔希尔分校 | Optimized human coagulation factor VIII gene expression cassette and application thereof |
WO2016127057A1 (en) | 2015-02-06 | 2016-08-11 | The University Of North Carolina At Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
AU2016215124B2 (en) * | 2015-02-06 | 2020-08-06 | The University Of North Carolina At Chapel Hill | Optimized human clotting Factor VIII gene expression cassettes and their use |
EP3253786A4 (en) * | 2015-02-06 | 2018-10-17 | The University of North Carolina at Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
AU2020264278B2 (en) * | 2015-02-06 | 2022-04-07 | The University Of North Carolina At Chapel Hill | Optimized human clotting Factor VIII gene expression cassettes and their use |
JP2018513678A (en) * | 2015-03-17 | 2018-05-31 | フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel | Optimized liver-specific expression system for FVIII and FIX |
WO2016146757A1 (en) | 2015-03-17 | 2016-09-22 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for fviii and fix |
US11007280B2 (en) | 2015-03-17 | 2021-05-18 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for FVIII and FIX |
US10815497B2 (en) | 2015-04-08 | 2020-10-27 | Genzyme Corporation | Production of oversized adeno-associated vectors |
WO2016164609A3 (en) * | 2015-04-08 | 2016-12-15 | Genzyme Corporation | Production of oversized adeno-associated vectors |
JP2021118724A (en) * | 2015-04-08 | 2021-08-12 | ジェンザイム・コーポレーション | Production of oversized adeno-associated vectors |
JP2018510648A (en) * | 2015-04-08 | 2018-04-19 | ジェンザイム・コーポレーション | Production of oversized adeno-associated vector |
EP3626274A3 (en) * | 2015-04-16 | 2020-06-17 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
US10058624B2 (en) | 2015-04-16 | 2018-08-28 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
US10898588B2 (en) | 2015-04-16 | 2021-01-26 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
WO2016183422A1 (en) | 2015-05-14 | 2016-11-17 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
JP2018515102A (en) * | 2015-05-14 | 2018-06-14 | セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド | Nucleic acid molecules containing spacers and methods of use thereof |
US11103597B2 (en) | 2015-05-14 | 2021-08-31 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers outside ITR |
EP3294309A4 (en) * | 2015-05-14 | 2019-01-16 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
US10512675B2 (en) * | 2015-09-24 | 2019-12-24 | Biomarin Pharmaceutical Inc. | Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same |
US20170087219A1 (en) * | 2015-09-24 | 2017-03-30 | Biomarin Pharmaceutical Inc. | Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same |
US11690898B2 (en) | 2015-09-24 | 2023-07-04 | Biomarin Pharmaceutical Inc. | Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same |
US11230720B2 (en) | 2015-10-14 | 2022-01-25 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
CN108473976B (en) * | 2015-10-28 | 2022-07-19 | 桑格摩生物治疗股份有限公司 | Liver-specific constructs, factor VIII expression cassettes, and methods of use thereof |
RU2774874C2 (en) * | 2015-10-28 | 2022-06-23 | Сангамо Терапьютикс, Инк. | Liver-specific structures, expression cassettes of factor viii and their application methods |
WO2017074526A1 (en) * | 2015-10-28 | 2017-05-04 | Sangamo Biosciences, Inc. | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
JP7324249B2 (en) | 2015-10-28 | 2023-08-09 | サンガモ セラピューティクス, インコーポレイテッド | Liver-specific constructs, factor VIII expression cassettes, and methods of their use |
JP2021176305A (en) * | 2015-10-28 | 2021-11-11 | サンガモ セラピューティクス, インコーポレイテッド | Liver-specific construct, factor viii expression cassette, and method for using the same |
US10143760B2 (en) | 2015-10-28 | 2018-12-04 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
US10828376B2 (en) | 2015-10-28 | 2020-11-10 | Sangamo Therapeutics, Inc. | Liver-specific constructs and methods of use thereof |
JP2018531614A (en) * | 2015-10-28 | 2018-11-01 | サンガモ セラピューティクス, インコーポレイテッド | Liver-specific construct, factor VIII expression cassette and method of use thereof |
CN108473976A (en) * | 2015-10-28 | 2018-08-31 | 桑格摩生物治疗股份有限公司 | Liver specificity construct, Factor IX expression cassette and its application method |
CN115141836A (en) * | 2015-10-28 | 2022-10-04 | 桑格摩生物治疗股份有限公司 | Liver-specific constructs, factor VIII expression cassettes, and methods of use thereof |
US11452782B2 (en) | 2015-10-28 | 2022-09-27 | Sangamo Therapeutics, Inc. | Liver-specific constructs factor VIII expression cassettes and methods of use thereof |
WO2017083762A1 (en) | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
US11492388B2 (en) | 2015-11-13 | 2022-11-08 | Takeda Pharmaceutical Company Limited | Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A |
US11254731B2 (en) | 2015-11-13 | 2022-02-22 | Takeda Pharmaceutical Company Limited | Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A |
US10189889B2 (en) | 2015-11-13 | 2019-01-29 | Baxalta Incorporated | Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A |
WO2017083764A1 (en) | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
US10189888B2 (en) | 2015-11-13 | 2019-01-29 | Baxalta Incorporated | Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A |
IL262215B1 (en) * | 2016-04-15 | 2023-03-01 | Univ Pennsylvania | Gene therapy for treating hemophilia a |
IL262215B2 (en) * | 2016-04-15 | 2023-07-01 | Univ Pennsylvania | Gene therapy for treating hemophilia a |
KR20190032274A (en) * | 2016-04-15 | 2019-03-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Gene Therapy for Hemophilia A Treatment |
CN109562191A (en) * | 2016-04-15 | 2019-04-02 | 宾夕法尼亚州大学信托人 | For treating the gene therapy of hemophilia A |
US11779656B2 (en) | 2016-04-15 | 2023-10-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia A |
US11191847B2 (en) | 2016-04-15 | 2021-12-07 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia B |
WO2017180857A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia a |
RU2762257C2 (en) * | 2016-04-15 | 2021-12-17 | Зе Трастис Оф Зе Юниверсити Оф Пенсильвания | Gene therapy for the treatment of hemophilia a |
TWI791433B (en) * | 2016-04-15 | 2023-02-11 | 賓州大學委員會 | Gene therapy for treating hemophilia a |
KR102450833B1 (en) * | 2016-04-15 | 2022-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Gene therapy for the treatment of hemophilia A |
US10888628B2 (en) | 2016-04-15 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia A |
AU2017248659B2 (en) * | 2016-04-15 | 2022-08-11 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia A |
JP2019527033A (en) * | 2016-05-16 | 2019-09-26 | バクスアルタ インコーポレイテッド | Anti-factor IX Padua antibody |
US11999798B2 (en) | 2016-05-16 | 2024-06-04 | Takeda Pharmaceutical Company Limited | Anti-factor IX padua antibodies |
JP7084878B2 (en) | 2016-05-16 | 2022-06-15 | 武田薬品工業株式会社 | Anti-factor IX Padua antibody |
US10960085B2 (en) | 2016-09-07 | 2021-03-30 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
WO2018162748A1 (en) | 2017-03-10 | 2018-09-13 | Genethon | Treatment of glycogen storage disease iii |
WO2018178067A1 (en) | 2017-03-27 | 2018-10-04 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
KR102386890B1 (en) | 2017-05-22 | 2022-04-15 | 다케다 야쿠힌 고교 가부시키가이샤 | Viral Vector Encoding Recombinant FIX Variant with Increased Expression for Hemophilia B Gene Therapy |
KR20200010443A (en) * | 2017-05-22 | 2020-01-30 | 박스알타 인코퍼레이티드 | Viral vector encoding recombinant FIX variant with increased expression for hemophilia B gene therapy |
WO2018217731A1 (en) | 2017-05-22 | 2018-11-29 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b |
KR20220050238A (en) * | 2017-05-22 | 2022-04-22 | 다케다 야쿠힌 고교 가부시키가이샤 | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b |
US10842853B2 (en) | 2017-05-22 | 2020-11-24 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B |
CN110945127A (en) * | 2017-05-22 | 2020-03-31 | 百深公司 | Viral vectors encoding recombinant FIX with increased expression for gene therapy of hemophilia B |
KR102551733B1 (en) | 2017-05-22 | 2023-07-06 | 다케다 야쿠힌 고교 가부시키가이샤 | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b |
US11951183B2 (en) | 2018-02-01 | 2024-04-09 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
US11891619B2 (en) | 2018-02-19 | 2024-02-06 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
WO2020018419A1 (en) | 2018-07-16 | 2020-01-23 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
US11517631B2 (en) | 2018-08-20 | 2022-12-06 | Ucl Business Ltd | Factor IX encoding nucleotides |
WO2020084162A1 (en) | 2018-10-26 | 2020-04-30 | Vrije Universiteit Brussel | Liver-specific nucleic acid regulatory elements and methods and use thereof |
WO2020084161A1 (en) | 2018-10-26 | 2020-04-30 | Vrije Universiteit Brussel | New tools for improving gene therapy and use thereof |
WO2020150375A1 (en) | 2019-01-16 | 2020-07-23 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
US11596671B2 (en) | 2019-02-01 | 2023-03-07 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression |
WO2020160303A1 (en) | 2019-02-01 | 2020-08-06 | Baxalta Incorporated | Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression |
WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
WO2021119357A2 (en) | 2019-12-12 | 2021-06-17 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
US11952585B2 (en) | 2020-01-13 | 2024-04-09 | Homology Medicines, Inc. | Methods of treating phenylketonuria |
WO2022061014A1 (en) * | 2020-09-16 | 2022-03-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
WO2022077806A1 (en) * | 2020-10-16 | 2022-04-21 | 广州吉妮欧生物科技有限公司 | Sars-cov-2 pseudovirus mouse in-vivo packaging system and preparation method therefor |
WO2022264040A1 (en) | 2021-06-14 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
WO2023006890A1 (en) | 2021-07-28 | 2023-02-02 | Vrije Universiteit Brussel | Improving the efficacy of muscle-targeted gene therapy |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2013336601A1 (en) | 2015-05-28 |
US20230022390A1 (en) | 2023-01-26 |
JP2016500519A (en) | 2016-01-14 |
CA2888931A1 (en) | 2014-05-01 |
US11419950B2 (en) | 2022-08-23 |
US20190240350A1 (en) | 2019-08-08 |
DK2911687T3 (en) | 2019-05-13 |
EP2911687B1 (en) | 2019-02-13 |
CA2888931C (en) | 2023-09-05 |
JP6454643B2 (en) | 2019-01-16 |
AU2013336601B2 (en) | 2018-01-25 |
EP2911687A1 (en) | 2015-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11419950B2 (en) | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof | |
EP3513802B1 (en) | Vector for liver-directed gene therapy of hemophilia and methods and use thereof | |
US20210369868A1 (en) | Optimized Liver-Specific Expression Systems for FVIII and FIX | |
JP6831779B2 (en) | Modified Factor IX and compositions, methods and uses for gene transfer into cells, organs and tissues | |
ES2436741T3 (en) | Improved expression of Factor IX in gene therapy vectors | |
JP6473416B2 (en) | Factor VIII sequence | |
Nathwani | Gene therapy for hemophilia | |
Chuah et al. | Gene therapy for hemophilia | |
AU2016343887A1 (en) | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof | |
WO2014063753A1 (en) | Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof | |
AU2009240054A1 (en) | Liver-specific nucleic acid regulatory elements and methods and use thereof | |
US20210379203A1 (en) | New Tools for Improving Gene Therapy and Use Thereof | |
WO2014016580A1 (en) | Transgene expression | |
WO2020160303A1 (en) | Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression | |
Hanley | The use of matrix attachment regions to enhance the in-vivo potency of rAAV vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13789223 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2888931 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14438571 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015538476 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013789223 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013336601 Country of ref document: AU Date of ref document: 20131025 Kind code of ref document: A |